Tumor necrosis factor-Î± (TNF-Î±) increases both in the from parkinsonian patients

Neuroscience Letters

165, 208-210

DOI: 10.1016/0304-3940(94)90746-3

Citation Report

#	Article	IF	Citations
1	Interleukin-1Î², interleukin-6, epidermal growth factor and transforming growth factor-Î± are elevated in the brain from parkinsonian patients. Neuroscience Letters, 1994, 180, 147-150.	1.0	770
2	Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 11294-11298.	3.3	382
3	Exposure of tumor necrosis factor-Î± to luminal membrane of bovine brain capillary endothelial cells cocultured with astrocytes induces a delayed increase of permeability and cytoplasmic stress fiber formation of actin. Journal of Neuroscience Research, 1995, 41, 717-726.	1.3	141
4	Brain Î²2-microglobulin levels are elevated in the striatum in Parkinson's diseaselevels are elevated in the striatum in Parkinson's disease. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1995, 9, 87-92.	1.2	94
5	Hypertriglyceridemia associated with Tumor Necrosis Factor-Î± in Hamster Cheek-pouch Carcinogenesis. Journal of Dental Research, 1995, 74, 1558-1563.	2.5	8
6	The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Research Reviews, 1995, 21, 195-218.	9.1	1,231
7	Transforming growth factor-Î²1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Neuroscience Letters, 1995, 193, 129-132.	1.0	157
8	Interleukin-1Î² and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neuroscience Letters, 1995, 202, 17-20.	1.0	719
9	Parkinson's Disease and Free Radicals.. Annals of the New York Academy of Sciences, 1996, 786, 206-216.	1.8	21
10	Intracarotid tumor necrosis factor-Î± administration increases the blood-brain barrier permeability in cerebral cortex of the newborn pig: quantitative aspects of double-labelling studies and confocal laser scanning analysis. Neuroscience Letters, 1996, 208, 85-88.	1.0	80
11	Interleukin (IL)-1Î², IL-2, IL-4, IL-6 and transforming growth factor-Î± levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neuroscience Letters, 1996, 211, 13-16.	1.0	496
12	bcl-2 Protein is increased in the brain from parkinsonian patients. Neuroscience Letters, 1996, 215, 137-139.	1.0	110
13	Production of tumor necrosis factor in spinal cord following traumatic injury in rats. Journal of Neuroimmunology, 1996, 69, 151-156.	1.1	141
14	The soluble form of Fas molecule is elevated in parkinsonian brain tissues. Neuroscience Letters, 1996, 220, 195-198.	1.0	94
16	Section Review Central & Peripheral Nervous Systems: Mechanisms of apoptosis as drug targets in the central nervous system. Expert Opinion on Therapeutic Patents, 1996, 6, 345-366.	2.4	3
17	Dissection of the pathologies induced by transmembrane and wild-type tumor necrosis factor in transgenic mice. Journal of Leukocyte Biology, 1996, 59, 518-525.	1.5	41
18	Inhibition by streptococcal immunopotentiator OK432 of lymph-node metastasis in hamster cheek-pouch carcinoma with enhancement of tumour necrosis factor-Î± and interleukin-6 in serum. Archives of Oral Biology, 1996, 41, 513-516.	0.8	2
19	Glial expression of cytokines in the brains of cerebrovascular disease patients. Acta Neuropathologica, 1996, 92, 281-287.	3.9	79

#	Article	IF	Citations
20	The Role of Inflammation and Cytokines in Brain Injury. Neuroscience and Biobehavioral Reviews, 1996, 20, 445-452.	2.9	371
21	Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Journal of Neural Transmission, 1996, 103, 1077-1081.	1.4	79
22	Interleukin (IL)-1Î², IL-6, Tumor Necrosis Factor-Î±, Epidermal Growth Factor, and Î²2-Microglobulin Levels Are Elevated in Gingival Crevicular Fluid during Human Orthodontic Tooth Movement. Journal of Dental Research, 1996, 75, 562-567.	2.5	284
23	Interferon-Î³ Potentiates Interleukin (IL)-6 and Tumor Necrosis Factor-Î± But Not IL-1Î² Induced by Endotoxin in the Brain. Endocrinology, 1997, 138, 5220-5226.	1.4	28
24	Inhibition of p75 Tumor Necrosis Factor Receptor by Antisense Oligonucleotides Increases Hypoxic Injury and Î²-Amyloid Toxicity in Human Neuronal Cell Line. Journal of Biological Chemistry, 1997, 272, 3550-3553.	1.6	90
25	The Neuroimmune Hypothesis in Parkinson's Disease. Reviews in the Neurosciences, 1997, 8, 29-34.	1.4	20
26	T-lymphocyte tumor necrosis factor-Î± receptor binding in patients with Parkinson's disease. Journal of the Neurological Sciences, 1997, 149, 41-45.	0.3	15
27	Inflammatory Cytokines in the CNS. CNS Drugs, 1997, 7, 214-228.	2.7	39
28	Effects of tumor necrosis factor on receptor-mediated endocytosis and barrier functions of bovine brain capillary endothelial cell monolayers. Journal of Neuroimmunology, 1997, 74, 173-184.	1.1	37
29	Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice. Neuroscience Letters, 1997, 234, 123-126.	1.0	39
30	TNF-Î± expressed in the brain of transgenic mice lowers central tyroxine hydroxylase immunoreactivity and alters grooming behavior. Neuroscience Letters, 1997, 238, 65-68.	1.0	57
31	Tumor Necrosis Factor-Î±: a Neuromodulator in the CNS. Neuroscience and Biobehavioral Reviews, 1997, 21, 603-613.	2.9	163
32	Neurodegeneration induced by MoMuLV-ts1 and increased expression of Fas and TNF-Î± in the central nervous system. Brain Research, 1998, 779, 1-8.	1.1	55
33	Preventive actions of a synthetic antioxidant in a novel animal model of AIDS dementia. Brain Research, 1998, 795, 349-357.	1.1	40
34	Cellular localization of tumor necrosis factor alpha following focal cerebral ischemia in mice. Brain Research, 1998, 801, 1-8.	1.1	79
35	Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1Î² and nerve growth factor in the striatum. Neuroscience Letters, 1998, 250, 25-28.	1.0	65
36	Exploratory and Displacement Behavior in Transgenic Mice Expressing High Levels of Brain TNF-Î±. Physiology and Behavior, 1998, 63, 571-576.	1.0	54
37	Glial cells and inflammation in parkinson's disease: A role in neurodegeneration?. Annals of Neurology, 1998, 44, S115-20.	2.8	289

#	Article	IF	Citations
38	Cytokine-Neurotransmitter Interactions in the Brain. NeuroSignals, 1998, 7, 33-44.	0.5	46
39	Experimental Destruction of Substantia Nigra Initiated by Parkinson Disease Immunoglobulins. Archives of Neurology, 1998, 55, 1075.	4.9	111
40	Effects of Cerebrospinal Fluid From Patients With Parkinson Disease on Dopaminergic Cells. Archives of Neurology, 1999, 56, 194.	4.9	46
41	Anti-proliferative Capsular-like Polysaccharide Antigen from Actinobacillus actinomycetemcomitans Induces Apoptotic Cell Death in Mouse Osteoblastic MC3T3-E1 Cells. Journal of Dental Research, 1999, 78, 1230-1237.	2.5	32
42	The Pivotal Role of Iron in NF-kappaB Activation and Nigrostriatal Dopaminergic Neurodegeneration: Prospects for Neuroprotection in Parkinson's Disease with Iron Chelators. Annals of the New York Academy of Sciences, 1999, 890, 7-25.	1.8	81
43	Protective effects of the TNF-ceramide pathway against glutamate neurotoxicity on cultured mesencephalic neurons. Brain Research, 1999, 819, 170-173.	1.1	44
44	Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Annals of Neurology, 1999, 46, 598-605.	2.8	894
45	Nerve growth factor inhibits apoptosis induced by tumor necrosis factor in PC12 cells. Journal of Neuroscience Research, 1999, 55, 269-277.	1.3	37
46	NGF-resistant PC12 cell death induced by arachidonic acid is accompanied by a decrease of active PKC zeta and nuclear factor kappa B. Journal of Neuroscience Research, 1999, 57, 219-226.	1.3	49
47	Increase in level of tumor necrosis factor (TNF)-Î± in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic l-DOPA on the TNF-Î± induction. Neuroscience Letters, 1999, 268, 101-104.	1.0	77
48	Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neuroscience Letters, 1999, 270, 45-48.	1.0	342
49	Tumor necrosis factor alpha expression produces increased bloodâ€“brain barrier permeability following temporary focal cerebral ischemia in mice. Molecular Brain Research, 1999, 69, 135-143.	2.5	133
50	Serial Determination of Tumor Necrosis Factor-Alpha Content in Rat Sciatic Nerve after Chronic Constriction Injury. Experimental Neurology, 1999, 160, 124-132.	2.0	126
51	Impaired cytokine production by peripheral blood mononuclear cells and monocytes/macrophages in Parkinson's disease. Acta Neurologica Scandinavica, 2000, 101, 159-164.	1.0	71
52	Glial cells and Parkinsonâ€™s disease. Journal of Neurology, 2000, 247, II58-II62.	1.8	57
53	Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from Parkinsonian brain. Journal of Neural Transmission, 2000, 107, 335-341.	1.4	255
54	Genetic analysis of immunomodulating factors in sporadic Parkinson's disease. Journal of Neural Transmission, 2000, 107, 553-562.	1.4	86
55	Changes in cytokines and neurotrophins in Parkinsonâ€™s disease. , 2000, , 277-290.		259

#	Article	IF	Citations
56	Cytokines in Parkinsonâ€™s disease. , 2000, , 143-151.		132
58	Inflammatory Regulators in Parkinson's Disease: iNOS, Lipocortin-1, and Cyclooxygenases-1 and -2. Molecular and Cellular Neurosciences, 2000, 16, 724-739.	1.0	442
59	The Single Intranigral Injection of LPS as a New Model for Studying the Selective Effects of Inflammatory Reactions on Dopaminergic System. Neurobiology of Disease, 2000, 7, 429-447.	2.1	373
60	Increase in level of tumor necrosis factor-Î± in 6-hydroxydopamine-lesioned striatum in rats is suppressed by immunosuppressant FK506. Neuroscience Letters, 2000, 289, 165-168.	1.0	55
61	Inflammation and Alzheimer's disease. Neurobiology of Aging, 2000, 21, 383-421.	1.5	4,069
62	Crosslinking of Î±-synuclein by advanced glycation endproducts â€" an early pathophysiological step in Lewy body formation?. Journal of Chemical Neuroanatomy, 2000, 20, 253-257.	1.0	212
63	Advances in Research on Neurodegeneration. , 2000, , .		0
64	Rat extracorporeal circulation model for evaluation of systemic immunotoxicity. Toxicology Letters, 2000, 115, 63-70.	0.4	6
65	Tumor Necrosis Factor Î± Is Toxic to Embryonic Mesencephalic Dopamine Neurons. Experimental Neurology, 2001, 169, 219-230.	2.0	200
66	Time-dependent sensitization of corticotropin-releasing hormone, arginine vasopressin and c-fos immunoreactivity within the mouse brain in response to tumor necrosis factor-Î±. Neuroscience, 2001, 106, 137-148.	1.1	47
67	Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Progress in Neurobiology, 2001, 65, 135-172.	2.8	1,056
68	Glial cell line-derived neurotrophic factor in the substantia nigra from control and parkinsonian brains. Neuroscience Letters, 2001, 300, 179-181.	1.0	42
69	High-performance immunoaffinity chromatography, an immunoaffinity membrane for selective removal of plasma components, and safety evaluation of the latter system. Journal of Proteomics, 2001, 49, 241-251.	2.4	12
70	Lactoferrin is synthesized by activated microglia in the human substantia nigra and its synthesis by the human microglial CHME cell line is upregulated by tumor necrosis factor Î± or 1-methyl-4-phenylpyridinium treatment. Molecular Brain Research, 2001, 96, 103-113.	2.5	65
71	Alpha-synuclein expression is up-regulated in NTera2 cells during neuronal differentiation but unaffected by exposure to cytokines and neurotrophic factors. Parkinsonism and Related Disorders, 2001, 8, 7-17.	1.1	18
72	Does Parkinson??s Disease Have an Immunological Basis?. BioDrugs, 2001, 15, 351-355.	2.2	27
73	Microglial Activation and Dopaminergic Cell Injury: AnIn VitroModel Relevant to Parkinson's Disease. Journal of Neuroscience, 2001, 21, 8447-8455.	1.7	241
74	The role of glial cells in ParkinsonÊ¼s disease. Current Opinion in Neurology, 2001, 14, 483-489.	1.8	303

#	Article	IF	Citations
75	Caspase-8 Is an Effector in Apoptotic Death of Dopaminergic Neurons in Parkinson's Disease, But Pathway Inhibition Results in Neuronal Necrosis. Journal of Neuroscience, 2001, 21, 2247-2255.	1.7	242
76	Evolution of Cerebral Tumor Necrosis Factor-Î± Production During Human Ischemic Stroke. Stroke, 2001, 32, 1750-1758.	1.0	176
77	Neurochemical findings in the MPTP model of Parkinson's disease. Journal of Neural Transmission, 2001, 108, 1263-1282.	1.4	256
78	Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. Journal of Neurochemistry, 2001, 78, 1073-1082.	2.1	509
79	Ubiquitin C-terminal hydrolase-L1 (PGP9.5) expression in human neural cell lines following induction of neuronal differentiation and exposure to cytokines, neurotrophic factors or heat stress. Neuropathology and Applied Neurobiology, 2001, 27, 95-104.	1.8	31
80	TNF-? stimulates caspase-3 activation and apoptotic cell death in primary septo-hippocampal cultures. Journal of Neuroscience Research, 2001, 64, 121-131.	1.3	89
81	Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse, 2001, 39, 167-174.	0.6	272
82	Regulation of Bloodâ€"Brain Barrier Permeability. Microcirculation, 2001, 8, 89-104.	1.0	120
84	Apoptotic death of neurons exhibiting peripherin aggregates is mediated by the proinflammatory cytokine tumor necrosis factor-Î±. Journal of Cell Biology, 2001, 155, 217-226.	2.3	109
85	Oxidative Stress Indices in Parkinson's Disease: Biochemical Determination. , 2001, 62, 137-153.		5
86	Inflammation and Parkinsons Disease. Inflammation and Allergy: Drug Targets, 2002, 1, 221-242.	3.1	41
87	Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's disease. FASEB Journal, 2002, 16, 1474-1476.	0.2	340
88	Role of TNF-Î± Receptors in Mice Intoxicated with the Parkinsonian Toxin MPTP. Experimental Neurology, 2002, 177, 183-192.	2.0	81
89	An inflammatory review of Parkinsonâ€™s disease. Progress in Neurobiology, 2002, 68, 325-340.	2.8	297
90	Involvement of inflammatory cytokines in central nervous system injury. Progress in Neurobiology, 2002, 67, 161-172.	2.8	235
91	Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease. Neuroscience Letters, 2002, 326, 70-72.	1.0	96
92	Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-Î±, interleukin-1Î², and nitric oxide. Developmental Brain Research, 2002, 133, 27-35.	2.1	182
93	Murine tumor necrosis factor-Î± sensitizes plasma corticosterone activity and the manifestation of shock: modulation by histamine. Journal of Neuroimmunology, 2002, 131, 60-69.	1.1	22

#	Article	IF	Citations
94	Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-ÎºB) activation and cell death by tea extracts in neuronal cultures11Abbreviations: BT, Black Tea; EMSA, Electromobility Shift Assay; EGCG, (-)-Epigallocatechin-3-gallate; GT, Green Tea; NB SH-SY5Y cells, Human neuroblastoma SH-SY5Y cells; 6-OHDA, 6-hydroxydopamine; IL, Interleukin; LDH, Lactate Dehydrogenase; MPTP, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NF-ÎºB, nuclear factor-ÎºB; OS, Oxidative Stress; PD, Parkinsonâ€™s Disease;. Biochemical Pharmacology, 2002, 63, 21-29.	2.0	282
95	In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Movement Disorders, 2002, 17, 116-124.	2.2	210
96	Parkinson's disease: changes in apoptosis-related factors suggesting possible gene therapy. Journal of Neural Transmission, 2002, 109, 731-745.	1.4	75
97	Free radicals in Parkinson's disease. Journal of Neurology, 2002, 249, 1-1.	1.8	95
98	Relative Contribution of Different Receptor Subtypes in the Response of Neuroblastoma Cells to Tumor Necrosis Factor-Î±. Journal of Neurochemistry, 2002, 75, 1172-1179.	2.1	18
99	The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-Î±, IL-1Î² and IFN-Î³. Journal of Neurochemistry, 2002, 81, 150-157.	2.1	227
100	Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. Journal of Neurochemistry, 2002, 83, 167-175.	2.1	85
101	Lipopolysaccharide Intranigral Injection Induces Inflammatory Reaction and Damage in Nigrostriatal Dopaminergic System. Journal of Neurochemistry, 1998, 70, 1584-1592.	2.1	360
102	Induction of Nitric Oxide Synthase and Nitric Oxideâ€Mediated Apoptosis in Neuronal PC12 Cells After Stimulation with Tumor Necrosis FActorâ€Î±/Lipopolysaccharide. Journal of Neurochemistry, 1998, 71, 88-94.	2.1	186
103	Tumor Necrosis Factor-Î± Increases Lactoferrin Transcytosis Through the Blood-Brain Barrier. Journal of Neurochemistry, 2002, 73, 2491-2500.	2.1	43
104	Glial Cell Response: A Pathogenic Factor in Parkinson's Disease. Journal of NeuroVirology, 2002, 8, 551-558.	1.0	37
105	Additive Neuroprotective Effects of Creatine and a Cyclooxygenase 2 Inhibitor Against Dopamine Depletion in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease. Journal of Molecular Neuroscience, 2003, 21, 191-198.	1.1	74
106	Parkinson's disease and inflammatory changes. Neurotoxicity Research, 2003, 5, 411-417.	1.3	72
107	Brain sites of movement disorder: Genetic and environmental agents in neurodevelopmental perturbations. Neurotoxicity Research, 2003, 5, 1-26.	1.3	27
108	Tumor necrosis factor-?-induced cell death in U373 cells overexpressing ?-synuclein. Journal of Neuroscience Research, 2003, 73, 334-340.	1.3	37
109	Pathogenic role of glial cells in Parkinson's disease. Movement Disorders, 2003, 18, 121-129.	2.2	246
110	Immunohistochemical study of the expression of cytokines and nitric oxide synthases in brains of patients with dementia with Lewy bodies. Neuropathology, 2003, 23, 9-15.	0.7	58
111	Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation.. Environmental Health Perspectives, 2003, 111, 1065-1073.	2.8	240

#	Article	IF	Citations
112	Neuroprotection by bioactive components in medicinal and food plant extracts. Mutation Research - Reviews in Mutation Research, 2003, 544, 203-215.	2.4	106
113	Neurotrophic and Neuroprotective Effects of Tripchlorolide, an Extract of Chinese Herb Tripterygium wilfordii Hook F, on Dopaminergic Neurons. Experimental Neurology, 2003, 179, 28-37.	2.0	56
114	Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiology of Disease, 2003, 12, 35-45.	2.1	172
115	Neuroprotective Strategies in Parkinson???s Disease. CNS Drugs, 2003, 17, 729-762.	2.7	206
116	Activation of microglia by human neuromelanin is NFâ€ÎºBâ€dependent and involves p38 mitogenâ€activated protein kinase: implications for Parkinson's disease. FASEB Journal, 2003, 17, 1-20.	0.2	279
117	Caspase-1 and Caspase-8 Cleave and Inactivate Cellular Parkin. Journal of Biological Chemistry, 2003, 278, 23376-23380.	1.6	70
118	Pathogenic role of glial cells in Parkinson's disease. Advances in Molecular and Cell Biology, 2003, 31, 967-982.	0.1	7
119	Scintigraphic visualization of inflammation in neurodegenerative disorders. Nuclear Medicine Communications, 2003, 24, 209-221.	0.5	8
120	Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long term losses of dopamine neurons in offspring a potential new model of parkinson s disease. Frontiers in Bioscience - Landmark, 2003, 8, s826-837.	3.0	148
121	Blood vessels and Parkinsonism. Frontiers in Bioscience - Landmark, 2004, 9, 277.	3.0	34
122	Suppression of Proinflammatory Cytokines Interleukin-1Â and Tumor Necrosis Factor-Â in Astrocytes by a V1 Vasopressin Receptor Agonist: A cAMP Response Element-Binding Protein-Dependent Mechanism. Journal of Neuroscience, 2004, 24, 2226-2235.	1.7	60
123	Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. Journal of Neurochemistry, 2004, 89, 822-833.	2.1	183
124	Triptolide, a Chinese herbal extract, protects dopaminergic neurons from inflammation-mediated damage through inhibition of microglial activation. Journal of Neuroimmunology, 2004, 148, 24-31.	1.1	66
125	Autoimmune-induced damage of the midbrain dopaminergic system in lupus-prone mice. Journal of Neuroimmunology, 2004, 152, 83-97.	1.1	49
126	New Therapeutic Strategies and Drug Candidates for Neurodegenerative Diseases: p53 and TNF-Â Inhibitors, and GLP-1 Receptor Agonists. Annals of the New York Academy of Sciences, 2004, 1035, 290-315.	1.8	91
127	Cellular pathology of Parkinson?s disease: astrocytes, microglia and inflammation. Cell and Tissue Research, 2004, 318, 149-161.	1.5	327
128	Diagnostic staging of Parkinson?s disease: conceptual aspects. Journal of Neural Transmission, 2004, 111, 201-216.	1.4	133
129	Antiapoptotic effects of budipine. Journal of Neural Transmission, 2004, 111, 1365-1373.	1.4	0

#	Article	IF	Citations
130	Tumor necrosis factor reduces cAMP production in rat microglia. Glia, 2004, 48, 241-249.	2.5	17
131	TNF? increases activity of ?-glutamyl transpeptidase in cultured rat astroglial cells. Journal of Neuroscience Research, 2004, 75, 536-543.	1.3	13
132	Rescue of TNF?-inhibited neuronal cells by IGF-1 involves Akt and c-Jun N-terminal kinases. Journal of Neuroscience Research, 2004, 76, 466-474.	1.3	47
133	Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. Journal of Nutritional Biochemistry, 2004, 15, 506-516.	1.9	434
134	Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism and Related Disorders, 2004, 10, S3-S7.	1.1	498
135	The homozygote AA genotype of the Î±1-antichymotrypsin gene may confer protection against early-onset Parkinson's disease in women. Parkinsonism and Related Disorders, 2004, 10, 469-473.	1.1	5
136	Early Expression and Cellular Localization of Proinflammatory Cytokines Interleukin-1Î², Interleukin-6, and Tumor Necrosis Factor-Î± in Human Traumatic Spinal Cord Injury. Spine, 2004, 29, 966-971.	1.0	177
137	Bi-functional effects of ATP/P2 receptor activation on tumor necrosis factor-alpha release in lipopolysaccharide-stimulated astrocytes. Journal of Neurochemistry, 2005, 92, 525-535.	2.1	69
138	The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. European Journal of Neuroscience, 2005, 22, 317-330.	1.2	114
139	The MAP kinase pathway mediates transcytosis induced by TNF-Î± in anin vitroblood-brain barrier model. European Journal of Neuroscience, 2005, 22, 835-844.	1.2	35
140	Increased osteopontin expression following intranigral lipopolysaccharide injection in the rat. European Journal of Neuroscience, 2005, 21, 1911-1920.	1.2	23
141	Peripheral lipopolysaccharide induces apoptosis in the murine olfactory bulb. Brain Research, 2005, 1039, 116-129.	1.1	14
142	In mice, production of plasma IL-1 and IL-6 in response to MPTP is related to behavioral lateralization. Brain Research, 2005, 1045, 31-37.	1.1	8
143	Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons. Journal of Neural Transmission, 2005, 112, 111-119.	1.4	95
144	Multiple system atrophy. , 2005, , 623-662.		2
145	Oxidative Stress, Antioxidants and Neurodegenerative Diseases. Current Pharmaceutical Design, 2005, 11, 2033-2052.	0.9	126
146	The Role of Early Life Environmental Risk Factors in Parkinson Disease: What Is the Evidence?. Environmental Health Perspectives, 2005, 113, 1234-1238.	2.8	117
148	Inflammatory Process in Parkinsons Disease: Role for Cytokines. Current Pharmaceutical Design, 2005, 11, 999-1016.	0.9	370

#	Article	IF	Citations
149	Atypical Parkinsonian Disorders. , 2005, , .		10
150	Estrogen and Cytokines Production - The Possible Cause of Gender Differences in Neurological Diseases. Current Pharmaceutical Design, 2005, 11, 1017-1030.	0.9	112
151	Cellular distribution of interleukin-1Î±-immunoreactivity after MPTP intoxication in mice. Molecular Brain Research, 2005, 138, 156-163.	2.5	7
152	Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease. Neurobiology of Disease, 2005, 19, 96-107.	2.1	339
153	Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease. Neuroscience Letters, 2005, 375, 107-111.	1.0	43
154	Differential inflammatory activation of IL-6 (â^'/â^') astrocytes. Cytokine, 2005, 30, 47-55.	1.4	17
155	Oxidative stress and inflammation in Parkinson's disease: is there a causal link?. Experimental Neurology, 2005, 193, 279-290.	2.0	435
156	Blueberry- and spirulina-enriched diets enhance striatal dopamine recovery and induce a rapid, transient microglia activation after injury of the rat nigrostriatal dopamine system. Experimental Neurology, 2005, 196, 298-307.	2.0	86
157	Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits. Neuroscience, 2005, 135, 829-838.	1.1	54
158	CSF proteome: a protein repository for potential biomarker identification. Expert Review of Proteomics, 2005, 2, 57-70.	1.3	113
159	Matrix Metalloproteinase-3: A Novel Signaling Proteinase from Apoptotic Neuronal Cells That Activates Microglia. Journal of Neuroscience, 2005, 25, 3701-3711.	1.7	241
160	Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTPâ€induced neurotoxicity: role of TNFâ€Î± 1. FASEB Journal, 2006, 20, 670-682.	0.2	213
161	Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinsonâ€™s disease. AAPS Journal, 2006, 8, E606-E621.	2.2	95
162	Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiology of Aging, 2006, 27, 530-545.	1.5	144
163	Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease. Annals of the New York Academy of Sciences, 2003, 991, 120-131.	1.8	439
164	Cellular Models to Study Dopaminergic Injury Responses. Annals of the New York Academy of Sciences, 2003, 991, 140-151.	1.8	27
165	Gene Expression Profiles of Reactive Astrocytes in Dopamineâ€depleted Striatum. Brain Pathology, 2004, 14, 275-280.	2.1	48
166	Neuroprotective Strategies in Parkinson's Disease Using the Models of 6â€Hydroxydopamine and MPTP^a. Annals of the New York Academy of Sciences, 2000, 899, 262-273.	1.8	78

#	Article	IF	Citations
167	Paeoniflorin attenuates neuroinflammation and dopaminergic neurodegeneration in the MPTP model of Parkinson's disease by activation of adenosine A1 receptor. British Journal of Pharmacology, 2006, 148, 314-325.	2.7	114
168	Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinsonâ€™s disease: possible implications of glial cells. , 2006, , 53-65.		100
169	Cellular and Molecular Mechanisms of Parkinsonâ€™s Disease: Neurotoxins, Causative Genes, and Inflammatory Cytokines. Cellular and Molecular Neurobiology, 2006, 26, 779-800.	1.7	107
170	Reactive Macrophages Increase Oxidative Stress and Alpha-Synuclein Nitration During Death of Dopaminergic Neuronal Cells in Co-Culture: Relevance to Parkinsonâ€™s Disease. Neurochemical Research, 2006, 31, 85-94.	1.6	72
171	Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration. Acta Neuropathologica, 2006, 112, 517-530.	3.9	115
172	Neuroinflammation, oxidative stress, and the pathogenesis of Parkinsonâ€™s disease. Clinical Neuroscience Research, 2006, 6, 261-281.	0.8	305
173	Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease. Brain Research, 2006, 1118, 239-250.	1.1	48
174	An Inflammatory Pathomechanism for Parkinsons Disease?. Current Medicinal Chemistry, 2006, 13, 591-602.	1.2	60
175	Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Experimental and Molecular Medicine, 2006, 38, 333-347.	3.2	552
176	Urocortin Modulates Inflammatory Response and Neurotoxicity Induced by Microglial Activation. Journal of Immunology, 2007, 179, 6204-6214.	0.4	53
177	Microglial Activation and its Implications in the Brain Diseases. Current Medicinal Chemistry, 2007, 14, 1189-1197.	1.2	854
178	TNF-α Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets. Current Alzheimer Research, 2007, 4, 378-385.	0.7	178
179	Inflammatory Cytokine Gene Polymorphisms and Increased Risk of Parkinson Disease. Archives of Neurology, 2007, 64, 836.	4.9	133
181	Green and Black Tea in Brain Protection. , 2007, , 581-605.		2
182	Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiology of Aging, 2007, 28, 894-906.	1.5	119
183	Non-steroidal anti-inflammatory drugs in Parkinson's disease. Experimental Neurology, 2007, 205, 295-312.	2.0	212
184	Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention. Experimental Neurology, 2007, 208, 1-25.	2.0	491
185	p53 protein, interferon-Î³, and NF-ÎºB levels are elevated in the parkinsonian brain. Neuroscience Letters, 2007, 414, 94-97.	1.0	217

#	Article	IF	Citations
186	Developmental switch in the effects of TNFÎ± on ventral midbrain dopaminergic neurons. Neuroscience Research, 2007, 57, 296-305.	1.0	29
187	Neuroinflammation and Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 535-551.	1.0	63
188	The Role of Anti-Inflammatory Agents in Parkinson???s Disease. CNS Drugs, 2007, 21, 789-797.	2.7	87
189	Programmed cell death in Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 591-605.	1.0	8
190	Glial Reaction in Parkinsons Diseases: Inflammatory Activation Signaling of Glia as a Potential Therapeutic Target. Current Signal Transduction Therapy, 2007, 2, 77-90.	0.3	5
191	Tumor necrosis factor-Î± promoter polymorphism is associated with the risk of Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 300-304.	1.1	43
192	Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Journal of Neuroscience Research, 2007, 85, 1752-1761.	1.3	42
193	Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Reviews Neuroscience, 2007, 8, 57-69.	4.9	3,477
194	Tripchlorolide protects against MPTPâ€induced neurotoxicity in C57BL/6 mice. European Journal of Neuroscience, 2007, 26, 1500-1508.	1.2	35
195	Neuroprotective role of bradykinin because of the attenuation of pro-inflammatory cytokine release from activated microglia. Journal of Neurochemistry, 2007, 101, 397-410.	2.1	116
196	Cocaine exposure in vitro induces apoptosis in fetal locus coeruleus neurons through TNFâ€Î±â€mediated induction of Bax and phosphorylated câ€Jun NH₂â€terminal kinase. Journal of Neurochemistry, 2007, 103, 542-556.	2.1	31
197	TNFÎ± and TNF receptor 1 expression in the mixed neuronalâ€“glial cultures of hippocampal dentate gyrus exposed to glutamate or trimethyltin. Brain Research, 2007, 1131, 17-28.	1.1	63
198	Early inhibition of TNFÎ± increases 6-hydroxydopamine-induced striatal degeneration. Brain Research, 2007, 1147, 240-247.	1.1	19
199	Apoptotic neuronal death in Parkinson's disease: Involvement of nitric oxide. Brain Research Reviews, 2007, 54, 233-250.	9.1	116
200	Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-ÎºB and JNK activation and suppression of COX-2 activity. Journal of Neuroimmunology, 2007, 192, 89-98.	1.1	70
201	The medial and lateral substantia nigra in Parkinsonâ€™s disease: mRNA profiles associated with higher brain tissue vulnerability. Neurogenetics, 2007, 8, 83-94.	0.7	108
202	Src suppressed C kinase substrate regulates the lipopolysaccharide-induced TNF-Î± biosynthesis in rat astrocytes. Journal of Molecular Neuroscience, 2007, 32, 16-24.	1.1	20
203	Divergent Roles for Tumor Necrosis Factor-Î± in the Brain. Journal of NeuroImmune Pharmacology, 2007, 2, 140-153.	2.1	196

#	Article	IF	Citations
204	Age and regionâ€specific responses of microglia, but not astrocytes, suggest a role in selective vulnerability of dopamine neurons after 1â€methylâ€4â€phenylâ€1,2,3,6â€tetrahydropyridine exposure in monkeys. Glia, 2008, 56, 1199-1214.	2.5	57
205	Peripheral Lipopolysaccharide Administration Affects the Olfactory Dopamine System in Mice. Annals of the New York Academy of Sciences, 2008, 1148, 127-135.	1.8	10
206	Cyclooxygenaseâ€2 deficiency modifies the neurochemical effects, motor impairment and coâ€morbid anxiety provoked by paraquat administration in mice. European Journal of Neuroscience, 2008, 28, 707-716.	1.2	37
207	Dual effects of TNFÎ± on nerve fiber formation from ventral mesencephalic organotypic tissue cultures. Brain Research, 2008, 1215, 30-39.	1.1	10
208	Microglial activation is not prevented by tacrolimus but dopamine neuron damage is reduced in a rat model of Parkinson's disease progression. Brain Research, 2008, 1216, 78-86.	1.1	12
209	The influence of dexmedetomidine on ischemic rat hippocampus. Brain Research, 2008, 1218, 250-256.	1.1	72
210	Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. Journal of Cellular and Molecular Medicine, 2008, 12, 2263-2280.	1.6	258
211	JAK2-STAT3 signaling pathway mediates thrombin-induced proinflammatory actions of microglia in vitroâ˜†. Journal of Neuroimmunology, 2008, 204, 118-125.	1.1	74
212	Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability. Neurobiology of Disease, 2008, 32, 521-527.	2.1	92
213	Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. Journal of Neuroinflammation, 2008, 5, 4.	3.1	107
214	TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. Journal of Neuroinflammation, 2008, 5, 45.	3.1	698
215	Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFÎ±, and INFÎ³ concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neuroscience Letters, 2008, 441, 158-162.	1.0	251
216	Protective role of interlekin-1 alpha gene polymorphism in Chinese Han population with sporadic Parkinsonâ€™s disease. Neuroscience Letters, 2008, 445, 23-25.	1.0	17
217	A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. Neuropharmacology, 2008, 55, 654-660.	2.0	18
218	Natural killer cells of Parkinson's disease patients are set up for activation: A possible role for innate immunity in the pathogenesis of this disease. Parkinsonism and Related Disorders, 2008, 14, 46-51.	1.1	59
219	Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: Comorbidity between depression and neurodegenerative disorders. Progress in Neurobiology, 2008, 85, 1-74.	2.8	260
220	Intranigral Lentiviral Delivery of Dominant-negative TNF Attenuates Neurodegeneration and Behavioral Deficits in Hemiparkinsonian rats. Molecular Therapy, 2008, 16, 1572-1579.	3.7	106
221	Effects of TNFÎ±-Converting Enzyme Inhibition on Amyloid Î² Production and APP ProcessingIn VitroandIn Vivo. Journal of Neuroscience, 2008, 28, 12052-12061.	1.7	50

#	Article	IF	Citations
222	Inflammatory Cytokines in Acute Ischemic Stroke. Current Pharmaceutical Design, 2008, 14, 3574-3589.	0.9	284
223	Synergistic Neurotoxic Effects of Arsenic and Dopamine in Human Dopaminergic Neuroblastoma SH-SY5Y Cells. Toxicological Sciences, 2008, 102, 254-261.	1.4	45
224	Etiopathogenesis of Parkinson Disease: A New Beginning?. Neuroscientist, 2009, 15, 28-35.	2.6	70
226	Inflammatory Cytokines IL-1Î²and TNF-Î±Regulate p75^{NTR}Expression in CNS Neurons and Astrocytes by Distinct Cell-Type-Specific Signalling Mechanisms. ASN Neuro, 2009, 1, AN20090009.	1.5	49
227	Autoimmune disease and risk for Parkinson disease. Neurology, 2009, 73, 1462-1468.	1.5	111
228	Increased serum levels of soluble tumor necrosis factor-Î± receptor-1 in patients with Parkinson's disease. Journal of Neuroimmunology, 2009, 216, 122-125.	1.1	97
229	Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain. Journal of Neuroimmunology, 2009, 215, 65-72.	1.1	32
230	Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurology, The, 2009, 8, 382-397.	4.9	1,648
231	Beneficial effects of antioxidantâ€enriched diet for tyrosine hydroxylaseâ€positive neurons in ventral mesencephalic tissue in oculo grafts. Journal of Comparative Neurology, 2009, 515, 72-82.	0.9	5
232	Neurochemical biomarkers in the differential diagnosis of movement disorders. Movement Disorders, 2009, 24, 1411-1426.	2.2	37
233	Astrocyteâ€"neuron interactions in neurological disorders. Journal of Biological Physics, 2009, 35, 317-336.	0.7	144
234	Neuroprotective molecular mechanisms of (âˆ’)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes and Nutrition, 2009, 4, 283-296.	1.2	208
235	CXCR4 and CXCL12 Expression is Increased in the Nigro-Striatal System of Parkinsonâ€™s Disease. Neurotoxicity Research, 2009, 16, 318-328.	1.3	87
236	Circulating interleukin-10 and interleukin-12 in Parkinsonâ€™s disease. Acta Neurologica Scandinavica, 2009, 119, 332-337.	1.0	91
237	Targets for neuroprotection in Parkinson's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 676-687.	1.8	147
238	Inflammatory priming of the substantia nigra influences the impact of later paraquat exposure: Neuroimmune sensitization of neurodegeneration. Neurobiology of Aging, 2009, 30, 1361-1378.	1.5	72
239	The influence of microglia on the pathogenesis of Parkinson's disease. Progress in Neurobiology, 2009, 89, 277-287.	2.8	247
240	Cytokine Polymorphisms and Immunosenescence. , 2009, , 631-658.		0

#	Article	IF	Citations
241	Inflammatory Response in Parkinsonism. , 2009, , 245-252.		6
242	Increase of Secondary Processes of Microglial and Astroglial Cells After MPTP-Induced Degeneration in Substantia Nigra Pars Compacta of Non Human Primates. , 2009, , 253-258.		7
243	Glutathioneâ€"a review on its role and significance in Parkinson's disease. FASEB Journal, 2009, 23, 3263-3272.	0.2	273
244	MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats.. Behavioral Neuroscience, 2009, 123, 1261-1270.	0.6	48
245	Peripheral Chemo-Cytokine Profiles in Alzheimers and Parkinsons Diseases. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1229-1241.	1.1	76
246	Glycogen synthase kinase-3Î² inactivation inhibits tumor necrosis factor-Î± production in microglia by modulating nuclear factor Îºb and MLK3/JNK signaling cascades. Journal of Neuroinflammation, 2010, 7, 99.	3.1	101
247	The antioxidant drink â€œeffective microorganism-X (EM-X)â€•pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinsonâ€™s disease. Journal of Pharmacy and Pharmacology, 2010, 56, 649-654.	1.2	26
248	Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. FASEB Journal, 2010, 24, 2533-2545.	0.2	198
249	Interleukin-1Î² contributes to dopaminergic neuronal death induced by lipopolysaccharide-stimulated rat glia in vitro. Journal of Neuroimmunology, 2010, 226, 20-26.	1.1	48
250	Î±-Melanocyte-stimulating hormone modulates lipopolysaccharide plus interferon-Î³-induced tumor necrosis factor-Î± expression but not tumor necrosis factor-Î± receptor expression in cultured hypothalamic neurons. Journal of Neuroimmunology, 2010, 227, 52-59.	1.1	14
251	Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiology of Disease, 2010, 37, 510-518.	2.1	879
252	Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: A pathogenetically based approach. Neurobiology of Disease, 2010, 39, 229-241.	2.1	67
253	The roles of TNF in brain dysfunction and disease. , 2010, 128, 519-548.		190
254	Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cellular Signalling, 2010, 22, 977-983.	1.7	235
255	Transcriptional regulation of UCP4 by NF-ÎºB and its role in mediating protection against MPP+ toxicity. Free Radical Biology and Medicine, 2010, 49, 192-204.	1.3	17
256	Microglial Activation and Chronic Neurodegeneration. Neurotherapeutics, 2010, 7, 354-365.	2.1	747
257	Effect of prolonged exposure to diesel engine exhaust on proinflammatory markers in different regions of the rat brain. Particle and Fibre Toxicology, 2010, 7, 12.	2.8	140
258	Mitochondrial dysfunction and loss of Parkinson's diseaseâ€linked proteins contribute to neurotoxicity of manganeseâ€containing welding fumes. FASEB Journal, 2010, 24, 4989-5002.	0.2	2

#	Article	IF	Citations
259	Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation. Pharmaceuticals, 2010, 3, 1812-1841.	1.7	71
260	Vulnerability of mesostriatal dopaminergic neurons in Parkinsonâ€™s disease. Frontiers in Neuroanatomy, 2010, 4, 140.	0.9	55
261	Microglia Acquire Distinct Activation Profiles Depending on the Degree of Î±-Synuclein Neuropathology in a rAAV Based Model of Parkinson's Disease. PLoS ONE, 2010, 5, e8784.	1.1	207
262	Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases. CNS and Neurological Disorders - Drug Targets, 2010, 9, 120-127.	0.8	15
263	The mechanism of action of MPTP-induced neuroinflammation and its modulation by melatonin in rat astrocytoma cells, C6. Free Radical Research, 2010, 44, 1304-1316.	1.5	39
264	Mitochondrial dysfunction and loss of Parkinson's disease-linked proteins contribute to neurotoxicity of manganese-containing welding fumes. FASEB Journal, 2010, 24, 4989-5002.	0.2	75
265	Methanol Induces a Discrete Transcriptional Dysregulation that Leads to Cytokine Overproduction in Activated Lymphocytes. Toxicological Sciences, 2010, 117, 303-313.	1.4	6
266	Vinpocetine as a potent antiinflammatory agent. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9921-9922.	3.3	71
267	Peripherally injected lipopolysaccharide induces apoptosis in the subventricular zone of young adult mice. Neuroscience Letters, 2010, 481, 126-130.	1.0	6
268	The protective effect of avocado soybean unsaponifilables on brain ischemia/reperfusion injury in rat prefrontal cortex. British Journal of Neurosurgery, 2011, 25, 701-706.	0.4	11
269	Delayed Dominant-Negative TNF Gene Therapy Halts Progressive Loss of Nigral Dopaminergic Neurons in a Rat Model of Parkinson's Disease. Molecular Therapy, 2011, 19, 46-52.	3.7	94
270	MPTP and Oxidative Stress: Itâ€™s Complicated!. , 2011, , 187-209.		1
272	Running exercise protects the substantia nigra dopaminergic neurons against inflammation-induced degeneration via the activation of BDNF signaling pathway. Brain, Behavior, and Immunity, 2011, 25, 135-146.	2.0	175
273	Effects of d-cycloserine on MPTP-induced behavioral and neurological changes: Potential for treatment of Parkinson's disease dementia. Behavioural Brain Research, 2011, 219, 280-290.	1.2	62
274	Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neuroscience Research, 2011, 69, 337-342.	1.0	164
275	Cytokine expression and microglial activation in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2011, 17, 683-688.	1.1	64
276	Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 380-389.	2.5	56
277	Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. Neuroscience, 2011, 194, 250-261.	1.1	125

#	Article	IF	Citations
278	Pharmacological Therapy in Parkinson's Disease: Focus on Neuroprotection. CNS Neuroscience and Therapeutics, 2011, 17, 345-367.	1.9	28
279	The duality of TNF signaling outcomes in the brain: Potential mechanisms?. Experimental Neurology, 2011, 229, 198-200.	2.0	14
280	The Role of Neuroinflammation in Parkinson's Disease. , 2011, , 403-421.		8
281	Peripheral Inflammation Increases the Damage in Animal Models of Nigrostriatal Dopaminergic Neurodegeneration: Possible Implication in Parkinson's Disease Incidence. Parkinson's Disease, 2011, 2011, 1-10.	0.6	35
282	Bridging Molecular Genetics and Biomarkers in Lewy Body and Related Disorders. International Journal of Alzheimer's Disease, 2011, 2011, 1-18.	1.1	7
283	The Degenerating Substantia Nigra as a Susceptible Region for Gene Transfer-Mediated Inflammation. Parkinson's Disease, 2011, 2011, 1-8.	0.6	7
284	The Endotoxin-Induced Neuroinflammation Model of Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-25.	0.6	70
285	Transcriptional Factor NF-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î°</mml:mi></mml:math>B as a Target for Therapy in Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-8.	0.6	75
286	The Involvement of Neuroinflammation and Kynurenine Pathway in Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-11.	0.6	64
287	Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?. Parkinson's Disease, 2011, 2011, 1-14.	0.6	37
288	Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. British Journal of Pharmacology, 2011, 164, 1357-1391.	2.7	576
289	Preventive and therapeutic effects of caffeic acid against inflammatory injury in striatum of MPTP-treated mice. European Journal of Pharmacology, 2011, 670, 441-447.	1.7	66
290	Increases of pentraxin 3 plasma levels in patients with Parkinson's disease. Movement Disorders, 2011, 26, 2364-2370.	2.2	24
291	Chronic Dichlorvos Exposure: Microglial Activation, Proinflammatory Cytokines and Damage to Nigrostriatal Dopaminergic System. NeuroMolecular Medicine, 2011, 13, 251-265.	1.8	32
292	The role of tumor necrosis factor-Î± and TNF-Î± receptors in cerebral arteries following cerebral ischemia in rat. Journal of Neuroinflammation, 2011, 8, 107.	3.1	84
293	The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration. Journal of Neuroinflammation, 2011, 8, 137.	3.1	33
294	CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease. Journal of Neuroinflammation, 2011, 8, 154.	3.1	118
295	The acute inflammatory response to intranigral Î±-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. Journal of Neuroinflammation, 2011, 8, 166.	3.1	137

#	Article	IF	Citations
296	Glia: Initiators and progressors of pathology in Parkinson's disease. Movement Disorders, 2011, 26, 6-17.	2.2	383
297	Studies on Experimental Models. , 2011, , .		1
298	IFN-Î³ signaling, with the synergistic contribution of TNF-Î±, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell Death and Disease, 2011, 2, e142-e142.	2.7	212
299	MPTP-Induced Neuroinflammation Increases the Expression of Pro-Inflammatory Cytokines and Their Receptors in Mouse Brain. NeuroImmunoModulation, 2011, 18, 79-88.	0.9	92
300	Role of Resveratrol and its Analogues in the Treatment of Neurodegenerative Diseases: Focus on Recent Discoveries. CNS and Neurological Disorders - Drug Targets, 2011, 10, 849-862.	0.8	48
301	Neurobiology of Vascular Dementia. Journal of Aging Research, 2011, 2011, 1-11.	0.4	22
302	Genetic deletion of TNF receptor suppresses excitatory synaptic transmissionviareducing AMPA receptor synaptic localization in cortical neurons. FASEB Journal, 2012, 26, 334-345.	0.2	80
303	Isoquinolines And Beta-Carbolines As Neurotoxins And Neuroprotectants. , 2012, , .		8
304	Innate Inflammation in Parkinson's Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a009373-a009373.	2.9	97
305	Current Opinions and Perspectives on the Role of Immune System in the Pathogenesis of Parkinson's Disease. Current Pharmaceutical Design, 2012, 18, 200-208.	0.9	55
306	Imaging of microglia in patients with neurodegenerative disorders. Frontiers in Pharmacology, 2012, 3, 96.	1.6	98
307	Cytokine Gene Polymorphisms and Parkinson's Disease: A Meta-Analysis. Canadian Journal of Neurological Sciences, 2012, 39, 58-64.	0.3	30
308	Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. Methods, 2012, 56, 508-513.	1.9	38
309	Inflammation in Parkinson's Disease. Advances in Protein Chemistry and Structural Biology, 2012, 88, 69-132.	1.0	154
310	Interferon-Î³ plays a role in paraquat-induced neurodegeneration involving oxidative and proinflammatory pathways. Neurobiology of Aging, 2012, 33, 1411-1426.	1.5	74
311	Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology, 2012, 62, 2154-2168.	2.0	248
312	Emerging roles of microglial activation and non-motor symptoms in Parkinson's disease. Progress in Neurobiology, 2012, 98, 222-238.	2.8	84
313	Rosiglitazone, a PPAR-Î³ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats. Toxicology Letters, 2012, 213, 332-344.	0.4	54

#	Article	IF	Citations
314	The NAMPT inhibitor FK866 reverts the damage in spinal cord injury. Journal of Neuroinflammation, 2012, 9, 66.	3.1	57
315	Allosteric modulation of the group III mGlu₄ receptor provides functional neuroprotection in the 6â€hydroxydopamine rat model of Parkinson's disease. British Journal of Pharmacology, 2012, 166, 2317-2330.	2.7	55
316	Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Research Bulletin, 2012, 87, 10-20.	1.4	760
317	Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinsonâ€™s disease. Journal of Neuroinflammation, 2012, 9, 234.	3.1	13
318	Proteolytic activation of proapoptotic kinase protein kinase CÎ´ by tumor necrosis factor Î± death receptor signaling in dopaminergic neurons during neuroinflammation. Journal of Neuroinflammation, 2012, 9, 82.	3.1	66
319	Parkinsonâ€™s disease and immune system: is the culprit LRRKing in the periphery?. Journal of Neuroinflammation, 2012, 9, 94.	3.1	34
320	Acorus gramineus inhibits microglia mediated neuroinflammation and prevents neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson's disease. Journal of Ethnopharmacology, 2012, 144, 506-513.	2.0	19
321	The role of microgliaâ€“lymphocyte interaction in PD neuropathology. Basal Ganglia, 2012, 2, 123-130.	0.3	1
322	Neuro-protective effects of bee venom by suppression of neuroinflammatory responses in a mouse model of Parkinsonâ€™s disease: Role of regulatory T cells. Brain, Behavior, and Immunity, 2012, 26, 1322-1330.	2.0	64
323	Inflammatory cytokines and NT-proCNP in Parkinsonâ€™s disease patients. Cytokine, 2012, 60, 762-766.	1.4	116
324	Potential of Dâ€cycloserine in the treatment of behavioral and neuroinflammatory disorders in Parkinson's disease and studies that need to be performed before clinical trials. Kaohsiung Journal of Medical Sciences, 2012, 28, 407-417.	0.8	9
325	Alpha-synuclein: from secretion to dysfunction and death. Cell Death and Disease, 2012, 3, e350-e350.	2.7	239
326	Microglia activation-induced mesencephalic dopaminergic neurodegeneration â€" an in vitro model for Parkinsonâ€™s disease. Frontiers in Biology, 2012, 7, 404-411.	0.7	0
327	Ceramide sphingolipid signaling mediates Tumor Necrosis Factor (TNF)-dependent toxicity via caspase signaling in dopaminergic neurons. Molecular Neurodegeneration, 2012, 7, 45.	4.4	46
328	Inflammatory Pathways in Parkinsonâ€™s Disease; A BNE Microarray Study. Parkinson's Disease, 2012, 2012, 1-16.	0.6	51
329	Antioxidant-Enriched Diet Affects Early Microglia Accumulation and Promotes Regeneration of the Striatal Dopamine System after a 6-Hydroxidopamine-Induced Lesion in a Rat. Journal of Experimental Neuroscience, 2012, 6, JEN.S10424.	2.3	3
330	Adjunctive therapy in Parkinson's disease: the role of rasagiline. Neuropsychiatric Disease and Treatment, 2012, 8, 285.	1.0	5
331	PINK1 stimulates interleukin-1Î²-mediated inflammatory signaling via the positive regulation of TRAF6 and TAK1. Cellular and Molecular Life Sciences, 2012, 69, 3301-3315.	2.4	32

#	Article	IF	Citations
332	Subventricular Zone Under the Neuroinflammatory Stress and Parkinsonâ€™s Disease. Cellular and Molecular Neurobiology, 2012, 32, 777-785.	1.7	4
333	Exposure of foetal neural progenitor cells to ILâ€1Î² impairs their proliferation and alters their differentiation â€“ a role for maternal inflammation?. Journal of Neurochemistry, 2012, 120, 964-973.	2.1	73
334	Central nervous system inflammation in disease related conditions: Mechanistic prospects. Brain Research, 2012, 1446, 144-155.	1.1	85
335	Full and partial peroxisome proliferation-activated receptor-gamma agonists, but not delta agonist, rescue of dopaminergic neurons in the 6-OHDA Parkinsonian model is associated with inhibition of microglial activation and MMP expression. Journal of Neuroimmunology, 2012, 246, 69-77.	1.1	42
336	TNF-Î± protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. Journal of Neuroinflammation, 2012, 9, 23.	3.1	224
337	Tumor Necrosis Factor-alpha and the Roles it Plays in Homeostatic and Degenerative Processes Within the Central Nervous System. Journal of NeuroImmune Pharmacology, 2012, 7, 42-59.	2.1	284
338	Kynurenines in Parkinsonâ€™s disease: therapeutic perspectives. Journal of Neural Transmission, 2012, 119, 275-283.	1.4	34
339	Genetic determinants of neuronal vulnerability to apoptosis. Cellular and Molecular Life Sciences, 2013, 70, 71-88.	2.4	14
340	A peroxisome proliferator-activated receptor-Î´ agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinsonâ€™s disease. Neuroscience, 2013, 240, 191-203.	1.1	43
341	Tear levels of tumor necrosis factor-alpha in patients with Parkinson's disease. Neuroscience Letters, 2013, 553, 63-67.	1.0	63
342	Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future. Advances in Predictive, Preventive and Personalised Medicine, 2013, , .	0.6	3
344	THE PRESENCE OF RANKL-OPG COMPLEX IN HUMAN OSTEOSARCOMA U2OS. Journal of Immunoassay and Immunochemistry, 2013, 34, 356-364.	0.5	1
345	Neuroimmunological Processes in Parkinson's Disease and their Relation to Î±-Synuclein: Microglia as the Referee between Neuronal Processes and Peripheral Immunity. ASN Neuro, 2013, 5, AN20120066.	1.5	197
346	Commentary: Progressive inflammation as a contributing factor to early development of Parkinson's disease. Experimental Neurology, 2013, 241, 148-155.	2.0	34
347	Pre-treatment with silymarin reduces brain myeloperoxidase activity and inflammatory cytokines in 6-OHDA hemi-parkinsonian rats. Neuroscience Letters, 2013, 555, 106-111.	1.0	29
348	Cerebrospinal fluid inflammatory markers in Parkinsonâ€™s disease â€“ Associations with depression, fatigue, and cognitive impairment. Brain, Behavior, and Immunity, 2013, 33, 183-189.	2.0	214
349	Neural and Immune Mechanisms in the Pathogenesis of Parkinsonâ€™s Disease. Journal of NeuroImmune Pharmacology, 2013, 8, 189-201.	2.1	132
350	Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinsonâ€™s disease. Neurochemistry International, 2013, 62, 803-819.	1.9	250

#	Article	IF	Citations
351	Increase of oxidative stress by a novel PINK1 mutation, P209A. Free Radical Biology and Medicine, 2013, 58, 160-169.	1.3	19
352	Inflammation alters the expression of <scp>DMT</scp>1, <scp>FPN</scp>1 and hepcidin, and it causes iron accumulation in central nervous system cells. Journal of Neurochemistry, 2013, 126, 541-549.	2.1	288
353	The role of inflammation in sporadic and familial Parkinsonâ€™s disease. Cellular and Molecular Life Sciences, 2013, 70, 4259-4273.	2.4	153
354	Oxidative stress mediated neuronal damage in the corpus striatum of 6-hydroxydopamine lesioned Parkinson's rats: Neuroprotection by Serotonin, GABA and Bone Marrow Cells Supplementation. Journal of the Neurological Sciences, 2013, 331, 31-37.	0.3	26
355	Magnetic Resonance Spectroscopy to Assess NeuroInflammation and Neuropathic Pain. Journal of NeuroImmune Pharmacology, 2013, 8, 576-593.	2.1	225
356	An Update on CSF Biomarkers of Parkinsonâ€™s Disease. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 161-184.	0.6	5
357	MHCII Is Required for Â-Synuclein-Induced Activation of Microglia, CD4 T Cell Proliferation, and Dopaminergic Neurodegeneration. Journal of Neuroscience, 2013, 33, 9592-9600.	1.7	304
358	Colonic inflammation in Parkinson's disease. Neurobiology of Disease, 2013, 50, 42-48.	2.1	482
359	Inhibition of glycogen synthase kinase-3Î² by lithium chloride suppresses 6-hydroxydopamine-induced inflammatory response in primary cultured astrocytes. Neurochemistry International, 2013, 63, 345-353.	1.9	52
360	Modulating Microglia Activity with PPAR-Î³ Agonists: A Promising Therapy for Parkinsonâ€™s Disease?. Neurotoxicity Research, 2013, 23, 112-123.	1.3	54
361	Glial-Mediated Inflammation Underlying Parkinsonism. Scientifica, 2013, 2013, 1-15.	0.6	22
362	Pluripotent stem cell-derived dopaminergic neurons as models of neurodegeneration. Future Neurology, 2013, 8, 649-661.	0.9	1
363	New Perspectives in Nuclear Neurology for the Evaluation of Parkinson's Disease. Journal of Parkinson's Disease, 2013, 3, 301-323.	1.5	1
364	PINK1 Deficiency Enhances Inflammatory Cytokine Release from Acutely Prepared Brain Slices. Experimental Neurobiology, 2013, 22, 38-44.	0.7	59
365	Animal models of neurodegenerative diseases. Revista Brasileira De Psiquiatria, 2013, 35, S82-S91.	0.9	45
366	LRRK-2 as a Key Molecule Bridging Inflammation to Parkinson's Disease. Advances in Neuroimmune Biology, 2013, 4, 205-215.	0.7	0
367	State of the art paper Tumor necrosis factor inhibitors â€“ state of knowledge. Archives of Medical Science, 2014, 6, 1175-1185.	0.4	151
368	Kynurenines in CNS disease: regulation by inflammatory cytokines. Frontiers in Neuroscience, 2014, 8, 12.	1.4	288

#	Article	IF	Citations
369	Vaccination strategies for Parkinson disease. Human Vaccines and Immunotherapeutics, 2014, 10, 852-867.	1.4	35
370	Transient transfection of human CDNF gene reduces the 6-hydroxydopamine-induced neuroinflammation in the rat substantia nigra. Journal of Neuroinflammation, 2014, 11, 209.	3.1	56
371	Immune Responses in Parkinsonâ€™s Disease: Interplay between Central and Peripheral Immune Systems. BioMed Research International, 2014, 2014, 1-9.	0.9	91
372	Neurotoxicity following acute inhalation of aerosols generated during resistance spot weld-bonding of carbon steel. Inhalation Toxicology, 2014, 26, 720-732.	0.8	16
373	Tumor Necrosis Factor Alpha: A Link between Neuroinflammation and Excitotoxicity. Mediators of Inflammation, 2014, 2014, 1-12.	1.4	513
374	Immunomodulatory Therapeutics. , 2014, , 547-567.		0
375	Damage of Neuroblastoma Cell SH-SY5Y Mediated by MPP+ Inhibits Proliferation of T-Cell Leukemia Jurkat by Co-Culture System. International Journal of Molecular Sciences, 2014, 15, 10738-10750.	1.8	6
376	Biomarkers of Parkinsonâ€™s disease. , 2014, , 817-831.		0
377	Cytokine Profiling in Patients with VCPâ€Associated Disease. Clinical and Translational Science, 2014, 7, 29-32.	1.5	15
378	Microglial TNFâ€Î± mediates enhancement of dopaminergic degeneration by brain angiotensin. Glia, 2014, 62, 145-157.	2.5	65
379	Inhibition of prothrombin kringle-2-induced inflammation by minocycline protects dopaminergic neurons in the substantia nigra in vivo. NeuroReport, 2014, 25, 489-495.	0.6	14
380	Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease. Frontiers in Cellular Neuroscience, 2014, 8, 369.	1.8	68
381	Blood and cerebrospinal fluid markers in Parkinson's disease: current biomarker findings. Current Biomarker Findings, 0, , 1.	0.4	7
382	Peripheral Leukocyte Apoptosis in Patients with Parkinsonism: Correlation with Clinical Characteristics and Neuroimaging Findings. BioMed Research International, 2014, 2014, 1-7.	0.9	14
383	LRRK2 and neuroinflammation: partners in crime in Parkinsonâ€™s disease?. Journal of Neuroinflammation, 2014, 11, 52.	3.1	148
384	Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease. Neurobiology of Disease, 2014, 67, 191-202.	2.1	94
385	Analysis of cognition, motor performance and anxiety in young and aged tumor necrosis factor alpha receptor 1 and 2 deficient mice. Behavioural Brain Research, 2014, 258, 43-51.	1.2	35
386	DHA effects in Parkinson disease depression. Basal Ganglia, 2014, 4, 61-66.	0.3	20

#	Article	IF	Citations
387	Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease. Movement Disorders, 2014, 29, 527-531.	2.2	53
388	Escin attenuates behavioral impairments, oxidative stress and inflammation in a chronic MPTP/probenecid mouse model of Parkinson×³s disease. Brain Research, 2014, 1585, 23-36.	1.1	40
389	Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?. Ageing Research Reviews, 2014, 13, 107-114.	5.0	66
390	Neuroinflammation and Neurodegeneration. , 2014, , .		11
391	Silymarin improved 6-OHDA-induced motor impairment in hemi-parkisonian rats: behavioral and molecular study. DARU, Journal of Pharmaceutical Sciences, 2014, 22, 38.	0.9	33
392	Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study. BMC Neurology, 2014, 14, 113.	0.8	68
394	Public health and components of particulate matter: The changing assessment of black carbon. Journal of the Air and Waste Management Association, 2014, 64, 620-660.	0.9	217
395	A novel synthetic HTB derivative, BECT inhibits lipopolysaccharide-mediated inflammatory response by suppressing the p38 MAPK/JNK and NF-ÎºB activation pathways. Pharmacological Reports, 2014, 66, 471-479.	1.5	24
396	Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: Possible role of SOCS-1 in reducing pro-inflammatory responses. Innate Immunity, 2014, 20, 249-260.	1.1	118
397	Evaluation of Nigrostriatal Neurodegeneration and Neuroinflammation Following Repeated Intranasal 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Administration in Mice, an Experimental Model of Parkinsonâ€™s Disease. Neurotoxicity Research, 2014, 25, 24-32.	1.3	23
398	Peripheral Administration of the Selective Inhibitor of Soluble Tumor Necrosis Factor (TNF) XProÂ®1595 Attenuates Nigral Cell Loss and Glial Activation in 6-OHDA Hemiparkinsonian Rats. Journal of Parkinson's Disease, 2014, 4, 349-360.	1.5	74
399	Three-Dimensional Blood-Brain Barrier Model for in vitro Studies of Neurovascular Pathology. Scientific Reports, 2015, 5, 15222.	1.6	162
400	Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by<scp>l</scp>-DOPA?<sup />. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140190.	1.8	41
401	Risk of developing <scp>P</scp>arkinson's disease among patients with asthma: a nationwide longitudinal study. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1605-1612.	2.7	35
402	Targeting of Tumor Necrosis Factor Alpha Receptors as a Therapeutic Strategy for Neurodegenerative Disorders. Antibodies, 2015, 4, 369-408.	1.2	27
403	Brain region-specific gene expression profiles in freshly isolated rat microglia. Frontiers in Cellular Neuroscience, 2015, 9, 84.	1.8	85
404	Human pluripotent stem cell derived midbrain PITX3eGFP/w neurons: a versatile tool for pharmacological screening and neurodegenerative modeling. Frontiers in Cellular Neuroscience, 2015, 9, 104.	1.8	16
405	Abnormal lipopolysaccharide binding protein as marker of gastrointestinal inflammation in Parkinson disease. Frontiers in Neuroscience, 2015, 9, 306.	1.4	52

#	Article	IF	Citations
406	Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases. Mediators of Inflammation, 2015, 2015, 1-27.	1.4	154
407	Interrelation of Oxidative Stress and Inflammation in Neurodegenerative Disease: Role of TNF. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-18.	1.9	486
408	Pentoxifylline Neuroprotective Effects Are Possibly Related to Its Anti-Inflammatory and TNF-Alpha Inhibitory Properties, in the 6-OHDA Model of Parkinsonâ€™s Disease. Parkinson's Disease, 2015, 2015, 1-15.	0.6	19
409	Protein misfolding and dysregulated protein homeostasis in autoinflammatory diseases and beyond. Seminars in Immunopathology, 2015, 37, 335-347.	2.8	37
410	TNFR1 absence protects against memory deficit induced by sepsis possibly through over-expression of hippocampal BDNF. Metabolic Brain Disease, 2015, 30, 669-678.	1.4	20
411	Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy. Antibodies, 2015, 4, 48-70.	1.2	63
412	M1 and M2 immune activation in Parkinsonâ€™s Disease: Foe and ally?. Neuroscience, 2015, 302, 59-73.	1.1	151
413	Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study. Neurobiology of Aging, 2015, 36, 1097-1104.	1.5	133
414	Protection of MPTP-induced neuroinflammation and neurodegeneration by rotigotine-loaded microspheres. Life Sciences, 2015, 124, 136-143.	2.0	15
415	Modifying welding process parameters can reduce the neurotoxic potential of manganese-containing welding fumes. Toxicology, 2015, 328, 168-178.	2.0	34
416	Role of Î±-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease. Journal of Parkinson's Disease, 2015, 5, 1-19.	1.5	174
417	TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects. Neuroscience, 2015, 302, 2-22.	1.1	368
418	Sulfhydryl-mediated redox signaling in inflammation: role in neurodegenerative diseases. Archives of Toxicology, 2015, 89, 1439-1467.	1.9	32
419	New insights on Parkinsonâ€™s disease genes: the link between mitochondria impairment and neuroinflammation. Journal of Neural Transmission, 2015, 122, 1409-1419.	1.4	24
421	The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Medicine, 2015, 13, 68.	2.3	186
422	Î±-Asarone attenuates microglia-mediated neuroinflammation by inhibiting NF kappa B activation and mitigates MPTP-induced behavioral deficits in a mouse model of Parkinson's disease. Neuropharmacology, 2015, 97, 46-57.	2.0	93
423	Activation of MyD88-dependent TLR1/2 signaling by misfolded Î±-synuclein, a protein linked to neurodegenerative disorders. Science Signaling, 2015, 8, ra45.	1.6	228
424	Parkinson disease with REM sleep behavior disorder. Neurology, 2015, 84, 888-894.	1.5	77

#	Article	IF	Citations
425	Neurotoxicity effects of atrazine-induced SH-SY5Y human dopaminergic neuroblastoma cells via microglial activation. Molecular BioSystems, 2015, 11, 2915-2924.	2.9	32
426	Neuroinflammation in Lewy body dementia. Parkinsonism and Related Disorders, 2015, 21, 1398-1406.	1.1	68
427	Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinsonâ€™s disease. Journal of Neural Transmission, 2015, 122, 1633-1643.	1.4	15
429	Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Experimental Neurology, 2015, 273, 36-44.	2.0	58
430	Perfluorooctane sulfonate mediates microglial activation and secretion of TNF-Î± through Ca2+-dependent PKC-NF-ÐºB signaling. International Immunopharmacology, 2015, 28, 52-60.	1.7	23
431	Effects of Physical Exercise on Neuroinflammation, Neuroplasticity, Neurodegeneration, and Behavior. Neurorehabilitation and Neural Repair, 2015, 29, 577-589.	1.4	132
432	Neuroprotective effects of bee venom acupuncture therapy against rotenone-induced oxidative stress and apoptosis. Neurochemistry International, 2015, 80, 79-86.	1.9	65
433	TNF-Î± regulates miRNA targeting mitochondrial complex-I and induces cell death in dopaminergic cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 451-461.	1.8	92
434	Inflammation is genetically implicated in Parkinsonâ€™s disease. Neuroscience, 2015, 302, 89-102.	1.1	182
435	Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease. Neurobiology of Disease, 2015, 73, 377-387.	2.1	79
436	The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive?. Brain Research, 2015, 1617, 155-173.	1.1	78
437	VEGF-A Promotes Both Pro-angiogenic and Neurotrophic Capacities for Nerve Recovery After Compressive Neuropathy in Rats. Molecular Neurobiology, 2015, 51, 240-251.	1.9	16
439	Cerebrospinal fluid and blood biomarkers as outcome measures in clinical trials for Parkinson's disease. , 0, , 249-264.		0
440	Role of Mitochondria-Associated Endoplasmic Reticulum Membrane in Inflammation-Mediated Metabolic Diseases. Mediators of Inflammation, 2016, 2016, 1-18.	1.4	61
441	Prothrombin Kringle-2: A Potential Inflammatory Pathogen in the Parkinsonian Dopaminergic System. Experimental Neurobiology, 2016, 25, 147-155.	0.7	13
442	Altered Expression Patterns of Inflammation-Associated and Trophic Molecules in Substantia Nigra and Striatum Brain Samples from Parkinson's Disease, Incidental Lewy Body Disease and Normal Control Cases. Frontiers in Neuroscience, 2015, 9, 507.	1.4	21
443	Neuroprotective and Therapeutic Strategies against Parkinsonâ€™s Disease: Recent Perspectives. International Journal of Molecular Sciences, 2016, 17, 904.	1.8	146
444	Neuroinflammation in Movement Disorders. Handbook of Behavioral Neuroscience, 2016, 24, 771-782.	0.7	4

#	Article	IF	Citations
445	Increased peripheral inflammation in asymptomatic leucineâ€rich repeat kinase 2 mutation carriers. Movement Disorders, 2016, 31, 889-897.	2.2	76
446	Glial biomarkers in human central nervous system disease. Glia, 2016, 64, 1755-1771.	2.5	41
447	Ser(P)â€1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease. Movement Disorders, 2016, 31, 1543-1550.	2.2	144
448	What a gastrointestinal biopsy can tell us about Parkinson's disease?. Neurogastroenterology and Motility, 2016, 28, 966-974.	1.6	28
449	Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinsonâ€™s Disease. Cell, 2016, 167, 1469-1480.e12.	13.5	2,399
450	Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinsonâ€™s disease. Science Translational Medicine, 2016, 8, 368ra174.	5.8	143
451	Effects of WR1065 on 6-hydroxydopamine-induced motor imbalance: Possible involvement of oxidative stress and inflammatory cytokines. Neuroscience Letters, 2016, 627, 7-12.	1.0	17
452	6-Mercaptopurine attenuates tumor necrosis factor-Î± production in microglia through Nur77-mediated transrepression and PI3K/Akt/mTOR signaling-mediated translational regulation. Journal of Neuroinflammation, 2016, 13, 78.	3.1	49
453	Levels of IL-8 and TNF-Î± decrease in Parkinsonâ€™s disease. Neurological Research, 2016, 38, 98-102.	0.6	34
454	Anti-Inflammatory Modulation of Microglia via CD163-Targeted Glucocorticoids Protects Dopaminergic Neurons in the 6-OHDA Parkinson's Disease Model. Journal of Neuroscience, 2016, 36, 9375-9390.	1.7	99
455	Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease. JAMA Neurology, 2016, 73, 1316.	4.5	385
456	Caspase-1 causes truncation and aggregation of the Parkinsonâ€™s disease-associated protein Î±-synuclein. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9587-9592.	3.3	202
457	Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinsonâ€™s disease (PD): historical overview and future prospects. Journal of Neural Transmission, 2016, 123, 1255-1278.	1.4	71
458	Molecular changes in the postmortem parkinsonian brain. Journal of Neurochemistry, 2016, 139, 27-58.	2.1	74
459	Evidence for a role of adaptive immune response in the disease pathogenesis of the <scp>MPTP</scp> mouse model of Parkinson's disease. Glia, 2016, 64, 386-395.	2.5	56
460	Rho kinase II interference by small hairpin RNA ameliorates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Molecular Medicine Reports, 2016, 14, 4947-4956.	1.1	10
461	Gene-environment interactions linking air pollution and inflammation in Parkinson's disease. Environmental Research, 2016, 151, 713-720.	3.7	55
462	Neuroprotective Effects of Germinated Brown Rice in Rotenone-Induced Parkinsonâ€™s-Like Disease Rats. NeuroMolecular Medicine, 2016, 18, 334-346.	1.8	17

#	Article	IF	Citations
464	Widespread brain transcriptome alterations underlie the neuroprotective actions of dietary saffron. Journal of Neurochemistry, 2016, 139, 858-871.	2.1	14
465	Loss of collapsin response mediator protein 4 suppresses dopaminergic neuron death in an 1â€methylâ€4â€phenylâ€1,2,3,6â€tetrahydropyridineâ€induced mouse model of Parkinson's disease. Journal of Neurochemistry, 2016, 137, 795-805.	2.1	14
466	Progressive loss of nigrostriatal dopaminergic neurons induced by inflammatory responses to fipronil. Toxicology Letters, 2016, 258, 36-45.	0.4	15
467	Upregulation of Glutaredoxin-1 Activates Microglia and Promotes Neurodegeneration: Implications for Parkinson's Disease. Antioxidants and Redox Signaling, 2016, 25, 967-982.	2.5	35
468	Viral Vector-Based Modeling of Neurodegenerative Disorders: Parkinsonâ€™s Disease. Methods in Molecular Biology, 2016, 1382, 367-382.	0.4	19
469	Mapping inflammation onto mood: Inflammatory mediators of anhedonia. Neuroscience and Biobehavioral Reviews, 2016, 64, 148-166.	2.9	97
470	The role of TWEAK/Fn14 signaling in the MPTP-model of Parkinsonâ€™s disease. Neuroscience, 2016, 319, 116-122.	1.1	10
471	microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease. Journal of Neuroscience, 2016, 36, 2383-2390.	1.7	195
472	Intranasal brain delivery of cationic nanoemulsion-encapsulated TNFÎ± siRNA in prevention of experimental neuroinflammation. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 987-1002.	1.7	83
473	Growth/differentiation factor-15 deficiency compromises dopaminergic neuron survival and microglial response in the 6-hydroxydopamine mouse model of Parkinson's disease. Neurobiology of Disease, 2016, 88, 1-15.	2.1	40
474	Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease. Current Opinion in Pharmacology, 2016, 26, 87-95.	1.7	46
475	Gene Therapy for Neurological Disorders. Methods in Molecular Biology, 2016, , .	0.4	3
476	CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration. Neurotoxicity Research, 2016, 29, 364-380.	1.3	15
477	Inflammation and B-cell Lymphoma-2 Associated X Protein Regulate Zinc-Induced Apoptotic Degeneration of Rat Nigrostriatal Dopaminergic Neurons. Molecular Neurobiology, 2016, 53, 5782-5795.	1.9	22
478	Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. Progress in Neurobiology, 2017, 155, 171-193.	2.8	137
479	Microglial phenotypes in Parkinsonâ€™s disease and animal models of the disease. Progress in Neurobiology, 2017, 155, 57-75.	2.8	202
480	Ferroptosis and cell death mechanisms in Parkinson's disease. Neurochemistry International, 2017, 104, 34-48.	1.9	260
482	Inflammatory profile discriminates clinical subtypes in LRRK2â€associated Parkinson's disease. European Journal of Neurology, 2017, 24, 427.	1.7	56

#	Article	IF	Citations
483	The bidirectional gut-brain-microbiota axis as a potential nexus between traumatic brain injury, inflammation, and disease. Brain, Behavior, and Immunity, 2017, 66, 31-44.	2.0	134
484	Downregulation of miRâ€7116â€5p in microglia by MPP⁺ sensitizes TNFâ€Î± production to induce dopaminergic neuron damage. Glia, 2017, 65, 1251-1263.	2.5	54
485	Tau/Î±â€synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study. Movement Disorders, 2017, 32, 1066-1073.	2.2	44
486	Neurosteroid allopregnanolone attenuates motor disability and prevents the changes of neurexin 1 and postsynaptic density protein 95 expression in the striatum of 6-OHDA-induced ratsâ€™ model of Parkinsonâ€™s disease. Biomedicine and Pharmacotherapy, 2017, 88, 1188-1197.	2.5	16
487	Enhanced dopaminergic neurotoxicity mediated by MPTP in IL-32Î² transgenic mice. Neurochemistry International, 2017, 102, 79-88.	1.9	13
488	Systemic Inflammation in Lewy Body Diseases. Alzheimer Disease and Associated Disorders, 2017, 31, 346-356.	0.6	36
489	Neuroinflammation - A major cause for striatal dopaminergic degeneration in Parkinson's disease. Journal of the Neurological Sciences, 2017, 381, 308-314.	0.3	76
490	Cytokine profiling in the prefrontal cortex of Parkinson's Disease and Multiple System Atrophy patients. Neurobiology of Disease, 2017, 106, 269-278.	2.1	58
491	Potential repositioning of exemestane as a neuroprotective agent for Parkinsonâ€™s disease. Free Radical Research, 2017, 51, 633-645.	1.5	5
492	Depression and Anxiety in Parkinson's Disease. International Review of Neurobiology, 2017, 133, 623-655.	0.9	107
493	Microbes Tickling Your Tummy: the Importance of the Gut-Brain Axis in Parkinsonâ€™s Disease. Current Behavioral Neuroscience Reports, 2017, 4, 361-368.	0.6	44
494	Pathological Î±-synuclein exacerbates the progression of Parkinsonâ€™s disease through microglial activation. Toxicology Letters, 2017, 265, 30-37.	0.4	119
495	<scp>l</scp>â€DOPAâ€induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?. European Journal of Neuroscience, 2017, 45, 73-91.	1.2	56
496	Investigations on 16-Arylideno Steroids as a New Class of Neuroprotective Agents for the Treatment of Alzheimerâ€™s and Parkinsonâ€™s Diseases. ACS Chemical Neuroscience, 2017, 8, 186-200.	1.7	20
497	Anti-Inflammatory and Neuroprotective Effects of PGE2 EP4 Signaling in Models of Parkinsonâ€™s Disease. Journal of NeuroImmune Pharmacology, 2017, 12, 292-304.	2.1	21
498	MPP+-Lesioned Mice: an Experimental Model of Motor, Emotional, Memory/Learning, and Striatal Neurochemical Dysfunctions. Molecular Neurobiology, 2017, 54, 6356-6377.	1.9	31
499	Pyrethroid Insecticides Directly Activate Microglia Through Interaction With Voltage-Gated Sodium Channels. Toxicological Sciences, 2017, 155, 112-123.	1.4	43
500	Activation of Nur77 in microglia attenuates proinflammatory mediators production and protects dopaminergic neurons from inflammationâ€induced cell death. Journal of Neurochemistry, 2017, 140, 589-604.	2.1	32

#	Article	IF	Citations
501	Toll-like receptor 2 is increased in neurons in Parkinsonâ€™s disease brain and may contribute to alpha-synuclein pathology. Acta Neuropathologica, 2017, 133, 303-319.	3.9	200
502	Is the Enzyme ACMSD a Novel Therapeutic Target in Parkinsonâ€™s Disease?. Journal of Parkinson's Disease, 2017, 7, 577-587.	1.5	22
503	Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia. JCI Insight, 2017, 2, .	2.3	72
504	Qigong Exercise May Reduce Serum TNF-Î± Levels and Improve Sleep in People with Parkinsonâ€™s Disease: A Pilot Study. Medicines (Basel, Switzerland), 2017, 4, 23.	0.7	23
505	Mitochondria in the pathophysiology of Alzheimer s and Parkinson s diseases. Frontiers in Bioscience - Landmark, 2017, 22, 854-872.	3.0	89
506	Recent Advances in the Study of Bipolar/Rod-Shaped Microglia and their Roles in Neurodegeneration. Frontiers in Aging Neuroscience, 2017, 9, 128.	1.7	54
507	Brain Renin-Angiotensin System and Microglial Polarization: Implications for Aging and Neurodegeneration. Frontiers in Aging Neuroscience, 2017, 9, 129.	1.7	172
508	Mild Inflammatory Profile without Gliosis in the c-Rel Deficient Mouse Modeling a Late-Onset Parkinsonism. Frontiers in Aging Neuroscience, 2017, 9, 229.	1.7	12
509	Leucine-Rich Repeat Kinase 2 (LRRK2) Stimulates IL-1Î²-Mediated Inflammatory Signaling through Phosphorylation of RCAN1. Frontiers in Cellular Neuroscience, 2017, 11, 125.	1.8	16
510	Axonal Degeneration during Aging and Its Functional Role in Neurodegenerative Disorders. Frontiers in Neuroscience, 2017, 11, 451.	1.4	139
511	Animal Models for the Study of Human Neurodegenerative Diseases. , 2017, , 1109-1129.		4
512	The reninâ€“angiotensin system: a possible new target for depression. BMC Medicine, 2017, 15, 144.	2.3	98
513	Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinsonâ€™s disease. Journal of Neuroinflammation, 2017, 14, 164.	3.1	64
514	NADPH oxidases in Parkinsonâ€™s disease: a systematic review. Molecular Neurodegeneration, 2017, 12, 84.	4.4	111
515	Parkinsonâ€™s disease is associated with DNA methylation levels in human blood and saliva. Genome Medicine, 2017, 9, 76.	3.6	122
516	Cerebellar neurochemical and histopathological changes in rat model of Parkinsonâ€™s disease induced by intrastriatal injection of rotenone. General Physiology and Biophysics, 2017, 36, 99-108.	0.4	12
517	Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2. Brain, Behavior, and Immunity, 2018, 69, 591-602.	2.0	55
518	Discovering New Benefits From Old Drugs With Big Dataâ€”Promise for Parkinson Disease. JAMA Neurology, 2018, 75, 917.	4.5	5

#	Article	IF	Citations
519	Antiâ€"Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease. JAMA Neurology, 2018, 75, 939.	4.5	256
520	Impact of aging, Alzheimer's disease and Parkinson's disease on the blood-brain barrier transport of therapeutics. Advanced Drug Delivery Reviews, 2018, 135, 62-74.	6.6	78
521	Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinsonâ€™s Disease. Molecular Neurobiology, 2018, 55, 9139-9155.	1.9	55
522	LRRK2 Phosphorylation: Behind the Scenes. Neuroscientist, 2018, 24, 486-500.	2.6	17
523	Early activation of Egr-1 promotes neuroinflammation and dopaminergic neurodegeneration in an experimental model of Parkinson's disease. Experimental Neurology, 2018, 302, 145-154.	2.0	44
524	MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinsonâ€™s disease by targeting Nlrp3. Human Cell, 2018, 31, 106-115.	1.2	101
525	The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinsonâ€™s Disease. Brain, Behavior, and Immunity, 2018, 70, 21-35.	2.0	47
526	Acetyl-l-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats. Molecular Neurobiology, 2018, 55, 583-602.	1.9	42
527	Cyclooxygenase-2 Directs Microglial Activation-Mediated Inflammation and Oxidative Stress Leading to Intrinsic Apoptosis in Zn-Induced Parkinsonism. Molecular Neurobiology, 2018, 55, 2162-2173.	1.9	17
528	The interplay between inflammation, oxidative stress, DNA damage, DNA repair and mitochondrial dysfunction in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 309-321.	2.5	206
529	Cell Death Pathways: a Novel Therapeutic Approach for Neuroscientists. Molecular Neurobiology, 2018, 55, 5767-5786.	1.9	114
530	Differential contribution of microglia and monocytes in neurodegenerative diseases. Journal of Neural Transmission, 2018, 125, 809-826.	1.4	84
531	Updates on immunity and inflammation in Parkinson disease pathology. Journal of Neuroscience Research, 2018, 96, 379-390.	1.3	86
532	Studies on 16,17-Pyrazoline Substituted Heterosteroids as Anti-Alzheimer and Anti-Parkinsonian Agents Using LPS Induced Neuroinflammation Models of Mice and Rats. ACS Chemical Neuroscience, 2018, 9, 272-283.	1.7	29
533	An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition. Archives of Toxicology, 2018, 92, 41-82.	1.9	77
534	Autoimmune rheumatic diseases and the risk of Parkinson disease: a nationwide population-based cohort study in Taiwan. Annals of Medicine, 2018, 50, 83-90.	1.5	46
535	Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease. Experimental Neurology, 2018, 300, 179-187.	2.0	163
536	Neurotherapeutic Effects of Bee Venom in a Rotenone-Induced Mouse Model of Parkinsonâ€™s Disease. Neurophysiology, 2018, 50, 445-455.	0.2	9

#	Article	IF	Citations
537	Andrographolide does not protect against neuroinflammation in a Parkinsonism model: Focus on tumor necrosis factor alpha. Journal of Physics: Conference Series, 2018, 1073, 032036.	0.3	0
538	Immune system responses in Parkinson's disease: Early and dynamic. European Journal of Neuroscience, 2019, 49, 364-383.	1.2	104
539	Palm Fruit Bioactives modulate human astrocyte activity in vitro altering the cytokine secretome reducing levels of TNFÎ±, RANTES and IP-10. Scientific Reports, 2018, 8, 16423.	1.6	17
540	Cerebrospinal fluid pro-inflammatory cytokines differentiate parkinsonian syndromes. Journal of Neuroinflammation, 2018, 15, 305.	3.1	45
541	Metals and Parkinson's Disease: Mechanisms and Biochemical Processes. Current Medicinal Chemistry, 2018, 25, 2198-2214.	1.2	136
542	Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease. Frontiers in Neurology, 2018, 9, 1081.	1.1	91
543	Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response. Frontiers in Cellular Neuroscience, 2018, 12, 488.	1.8	482
544	Counteracting neuroinflammation in experimental Parkinsonâ€™s disease favors recovery of function: effects of Er-NPCs administration. Journal of Neuroinflammation, 2018, 15, 333.	3.1	16
545	Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches. Brain Sciences, 2018, 8, 177.	1.1	139
546	Î±-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinsonâ€™s Disease Pathogenesis. Frontiers in Neuroscience, 2018, 12, 626.	1.4	28
547	Ageing, Cellular Senescence and Neurodegenerative Disease. International Journal of Molecular Sciences, 2018, 19, 2937.	1.8	248
548	Damage to dopaminergic neurons by oxidative stress in Parkinson's disease (Review). International Journal of Molecular Medicine, 2018, 41, 1817-1825.	1.8	163
549	An Aqueous Extract of Herbal Medicine ALWPs Enhances Cognitive Performance and Inhibits LPS-Induced Neuroinflammation via FAK/NF-Îºb Signaling Pathways. Frontiers in Aging Neuroscience, 2018, 10, 269.	1.7	16
550	Impact of monomeric, oligomeric and fibrillar alpha-synuclein on astrocyte reactivity and toxicity to neurons. Biochemical Journal, 2018, 475, 3153-3169.	1.7	55
551	Cerebrospinal fluid concentrations of inflammatory markers in Parkinsonâ€™s disease and atypical parkinsonian disorders. Scientific Reports, 2018, 8, 13276.	1.6	104
552	Vitamin D protects dopaminergic neurons against neuroinflammation and oxidative stress in hemiparkinsonian rats. Journal of Neuroinflammation, 2018, 15, 249.	3.1	75
553	Role of Curcumin in Regulation of TNF-Î± Mediated Brain Inflammatory Responses. Recent Patents on Inflammation and Allergy Drug Discovery, 2018, 12, 69-77.	3.9	37
554	Electrolytes and Biochemical Changes in Cerebrospinal Fluid in Drowning. American Journal of Forensic Medicine and Pathology, 2018, 39, 236-241.	0.4	8

#	Article	IF	Citations
555	Modeling Parkinsonâ€™s Disease Using Patient-specific Induced Pluripotent Stem Cells. Journal of Parkinson's Disease, 2018, 8, 479-493.	1.5	34
556	Mitochondria at the Base of Neuronal Innate Immunity in Alzheimerâ€™s and Parkinsonâ€™s Diseases. , 2018, , .		1
557	LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages. EMBO Journal, 2018, 37, .	3.5	140
558	Linking Neuroinflammation and Neurodegeneration in Parkinsonâ€™s Disease. Journal of Immunology Research, 2018, 2018, 1-12.	0.9	327
559	Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity. Frontiers in Molecular Neuroscience, 2018, 11, 36.	1.4	75
560	Emerging Biosensing Technologies for Neuroinflammatory and Neurodegenerative Disease Diagnostics. Frontiers in Molecular Neuroscience, 2018, 11, 164.	1.4	25
561	A New Venue of TNF Targeting. International Journal of Molecular Sciences, 2018, 19, 1442.	1.8	96
562	Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease. Frontiers in Aging Neuroscience, 2018, 10, 109.	1.7	153
563	Regional microglia are transcriptionally distinct but similarly exacerbate neurodegeneration in a culture model of Parkinsonâ€™s disease. Journal of Neuroinflammation, 2018, 15, 139.	3.1	17
564	Inflammatory Bowel Disease and Parkinsonâ€™s Disease: A Nationwide Swedish Cohort Study. Inflammatory Bowel Diseases, 2019, 25, 111-123.	0.9	117
565	What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinsonâ€™s Disease Patients and Healthy Subjects with Parkinsonâ€™s-Associated LRRK2 Mutations?. Journal of Parkinson's Disease, 2019, 9, 467-488.	1.5	10
566	Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinsonâ€™s disease. Journal of Neuroinflammation, 2019, 16, 153.	3.1	76
567	Parkinsonâ€™s Disease: The Emerging Role of Gut Dysbiosis, Antibiotics, Probiotics, and Fecal Microbiota Transplantation. Journal of Neurogastroenterology and Motility, 2019, 25, 363-376.	0.8	105
568	Toll-like receptors and their therapeutic potential in Parkinsonâ€™s disease and Î±-synucleinopathies. Brain, Behavior, and Immunity, 2019, 81, 41-51.	2.0	81
569	Systemic and Intravitreal Antagonism of the TNFR1 Signaling Pathway Delays Axotomy-Induced Retinal Ganglion Cell Loss. Frontiers in Neuroscience, 2019, 13, 1096.	1.4	18
570	Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinsonâ€™s disease. Nature Communications, 2019, 10, 3945.	5.8	127
571	Neuroglia in Neurodegenerative Diseases. Advances in Experimental Medicine and Biology, 2019, , .	0.8	18
572	Aquaporinâ€4 deficiency reduces TGFâ€Î²1 in mouse midbrains and exacerbates pathology in experimental Parkinson's disease. Journal of Cellular and Molecular Medicine, 2019, 23, 2568-2582.	1.6	38

#	Article	IF	Citations
573	Glatiramer Acetate Reverses Motor Dysfunction and the Decrease in Tyrosine Hydroxylase Levels in a Mouse Model of Parkinson's Disease. Neuroscience, 2019, 414, 8-27.	1.1	20
574	Neuroprotective Potential of Small Molecule Phytochemicals in Stroke Therapy. , 2019, , 155-175.		2
575	Advancement in the Pathophysiology of Cerebral Stroke. , 2019, , .		5
576	Microglia-mediated neuroinflammation in neurodegenerative diseases. Seminars in Cell and Developmental Biology, 2019, 94, 112-120.	2.3	472
577	Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntingtonâ€™s disease by etanercept treatment. Scientific Reports, 2019, 9, 7202.	1.6	16
578	16,17-Nâ€²-(alky/arylsulfonyl)pyrazoline substituted neuroprotective heterosteroids: Synthesis, molecular docking and preclinical efficacy/toxicity studies in rodents. Steroids, 2019, 148, 114-124.	0.8	5
579	Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with Î±-synuclein fibrils. Neurobiology of Disease, 2019, 129, 67-78.	2.1	53
580	Rosmarinic acid attenuates inflammatory responses through inhibiting HMGB1/TLR4/NF-ÎºB signaling pathway in a mouse model of Parkinson's disease. Life Sciences, 2019, 223, 158-165.	2.0	62
581	Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinsonâ€™s disease. Journal of Neuroinflammation, 2019, 16, 50.	3.1	22
582	The role and therapeutic potential of connexins, pannexins and their channels in Parkinson's disease. Cellular Signalling, 2019, 58, 111-118.	1.7	24
583	Ablation of the pro-inflammatory master regulator miR-155 does not mitigate neuroinflammation or neurodegeneration in a vertebrate model of Gaucher's disease. Neurobiology of Disease, 2019, 127, 563-569.	2.1	19
584	The effects of acupuncture and electroacupuncture on Parkinson's disease: Current status and future perspectives for molecular mechanisms. Journal of Cellular Biochemistry, 2019, 120, 12156-12166.	1.2	27
585	Peripheral-Central Neuroimmune Crosstalk in Parkinson's Disease: What Do Patients and Animal Models Tell Us?. Frontiers in Neurology, 2019, 10, 232.	1.1	48
586	Biomarkers of Parkinson's Disease. , 2019, , 895-909.		0
587	Anti-neuroinflammation ameliorates systemic inflammation-induced mitochondrial DNA impairment in the nucleus of the solitary tract and cardiovascular reflex dysfunction. Journal of Neuroinflammation, 2019, 16, 224.	3.1	19
588	Intrastriatal injection of preformed alpha-synuclein fibrils alters central and peripheral immune cell profiles in non-transgenic mice. Journal of Neuroinflammation, 2019, 16, 250.	3.1	85
589	Pharmacological Targeting of Microglial Activation: New Therapeutic Approach. Frontiers in Cellular Neuroscience, 2019, 13, 514.	1.8	94
590	Immunology of West Nile Virus Infection and the Role of Alpha-Synuclein as a Viral Restriction Factor. Viral Immunology, 2019, 32, 38-47.	0.6	19

#	Article	IF	Citations
591	Brain-Resident T Cells Following Viral Infection. Viral Immunology, 2019, 32, 48-54.	0.6	26
592	Î±-Synuclein and Glia in Parkinsonâ€™s Disease: A Beneficial or a Detrimental Duet for the Endo-Lysosomal System?. Cellular and Molecular Neurobiology, 2019, 39, 161-168.	1.7	40
593	Knockdown of cathepsin D protects dopaminergic neurons against neuroinflammationâ€mediated neurotoxicity through inhibition of NFâ€ÎºB signalling pathway in Parkinson's disease model. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 337-349.	0.9	14
594	The risk of Parkinsonâ€™s disease in inflammatory bowel disease: A systematic review and meta-analysis. Digestive and Liver Disease, 2019, 51, 38-42.	0.4	87
595	Gene Dysfunction Mediates Immune Response to Dopaminergic Degeneration in Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 803-811.	1.7	7
596	The unlikely partnership between <scp>LRRK</scp>2 and Î±â€synuclein in Parkinson's disease. European Journal of Neuroscience, 2019, 49, 339-363.	1.2	35
597	The role of catecholamines in HIV neuropathogenesis. Brain Research, 2019, 1702, 54-73.	1.1	40
598	Risk of Parkinsonâ€™s disease after colectomy: longitudinal follow-up study using a national sample cohort. Journal of Neurology, 2020, 267, 513-521.	1.8	3
599	Impaired metabolism of kynurenine and its metabolites in CSF of parkinsonâ€™s disease. Neuroscience Letters, 2020, 714, 134576.	1.0	32
600	Systemic activation of NLRP3 inflammasome and plasma Î±-synuclein levels are correlated with motor severity and progression in Parkinsonâ€™s disease. Journal of Neuroinflammation, 2020, 17, 11.	3.1	127
601	Innate and adaptive immune responses in Parkinson's disease. Progress in Brain Research, 2020, 252, 169-216.	0.9	64
602	Alterations of the gut microbiota with antibiotics protects dopamine neuron loss and improve motor deficits in a pharmacological rodent model of Parkinson's disease. Experimental Neurology, 2020, 325, 113159.	2.0	69
603	Risk of Parkinsonâ€™s disease among patients with herpes zoster: a nationwide longitudinal study. CNS Spectrums, 2020, 25, 797-802.	0.7	9
604	NF-ÎºB-Mediated Neuroinflammation in Parkinsonâ€™s Disease and Potential Therapeutic Effect of Polyphenols. Neurotoxicity Research, 2020, 37, 491-507.	1.3	121
605	Asparagine endopeptidase inhibitor protects against fenpropathrin-induced neurodegeneration via suppressing Î±-synuclein aggregation and neuroinflammation. European Journal of Pharmacology, 2020, 888, 173586.	1.7	10
606	Glutamate-induced excitotoxicity in Parkinson's disease: The role of glial cells. Journal of Pharmacological Sciences, 2020, 144, 151-164.	1.1	163
607	Tumour necrosis factor induces increased production of extracellular amyloid-Î²- and Î±-synuclein-containing aggregates by human Alzheimerâ€™s disease neurons. Brain Communications, 2020, 2, fcaa146.	1.5	14
608	Activation of TNFR1 and TLR4 following oxygen glucose deprivation promotes mitochondrial fission in C6 astroglial cells. Cellular Signalling, 2020, 75, 109714.	1.7	5

#	Article	IF	Citations
609	The Role of Glial Mitochondria in Î±-Synuclein Toxicity. Frontiers in Cell and Developmental Biology, 2020, 8, 548283.	1.8	13
610	Microorganismos relacionados con un mayor riesgo de presentar la enfermedad de Parkinson. NeurologÃa, 2023, 38, 495-503.	0.3	2
611	Immunoinflammatory Aspects of Parkinsonâ€™s Disease. Neuroscience and Behavioral Physiology, 2020, 50, 1127-1135.	0.2	0
612	Neuroinflammation and protein pathology in Parkinsonâ€™s disease dementia. Acta Neuropathologica Communications, 2020, 8, 211.	2.4	86
613	Overview of General and Discriminating Markers of Differential Microglia Phenotypes. Frontiers in Cellular Neuroscience, 2020, 14, 198.	1.8	476
614	Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson's disease: A case series. Neurobiology of Disease, 2020, 144, 105027.	2.1	34
615	Lactobacillus plantarum PS128 alleviates neurodegenerative progression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse models of Parkinsonâ€™s disease. Brain, Behavior, and Immunity, 2020, 90, 26-46.	2.0	86
616	Plasma immune markers in an idiopathic REM sleep behavior disorder cohort. Parkinsonism and Related Disorders, 2020, 78, 145-150.	1.1	22
617	Subthalamic nucleus deep brain stimulation suppresses neuroinflammation by Fractalkine pathway in Parkinsonâ€™s disease rat model. Brain, Behavior, and Immunity, 2020, 90, 16-25.	2.0	26
618	Computational modelling of TNFÎ± related pathways regulated by neuroinflammation, oxidative stress and insulin resistance in neurodegeneration. Applied Network Science, 2020, 5, .	0.8	3
619	Valeric Acid Protects Dopaminergic Neurons by Suppressing Oxidative Stress, Neuroinflammation and Modulating Autophagy Pathways. International Journal of Molecular Sciences, 2020, 21, 7670.	1.8	39
620	In Search of Effective Treatments Targeting Î±-Synuclein Toxicity in Synucleinopathies: Pros and Cons. Frontiers in Cell and Developmental Biology, 2020, 8, 559791.	1.8	14
621	When It Comes to an End: Oxidative Stress Crosstalk with Protein Aggregation and Neuroinflammation Induce Neurodegeneration. Antioxidants, 2020, 9, 740.	2.2	52
622	P2X7 Receptors Amplify CNS Damage in Neurodegenerative Diseases. International Journal of Molecular Sciences, 2020, 21, 5996.	1.8	75
623	MMP13 Expression Is Increased Following Mutant Î±-Synuclein Exposure and Promotes Inflammatory Responses in Microglia. Frontiers in Neuroscience, 2020, 14, 585544.	1.4	12
624	Biological effects of inhaled hydraulic fracturing sand dust VII. Neuroinflammation and altered synaptic protein expression. Toxicology and Applied Pharmacology, 2020, 409, 115300.	1.3	9
625	Multiple-Hit Hypothesis in Parkinsonâ€™s Disease: LRRK2 and Inflammation. Frontiers in Neuroscience, 2020, 14, 376.	1.4	43
626	Inflammation in Neurological Disorders: The Thin Boundary Between Brain and Periphery. Antioxidants and Redox Signaling, 2020, 33, 191-210.	2.5	68

#	Article	IF	Citations
627	A systematic review of minor phytocannabinoids with promising neuroprotective potential. British Journal of Pharmacology, 2020, 177, 4330-4352.	2.7	53
628	Innate Immunity: A Common Denominator between Neurodegenerative and Neuropsychiatric Diseases. International Journal of Molecular Sciences, 2020, 21, 1115.	1.8	70
629	The pesticide fipronil injected into the substantia nigra of male rats decreases striatal dopamine content: A neurochemical, immunohistochemical and behavioral study. Behavioural Brain Research, 2020, 384, 112562.	1.2	18
630	The Immunomodulary Effects of Systematic Exercise in Older Adults and People with Parkinsonâ€™s Disease. Journal of Clinical Medicine, 2020, 9, 184.	1.0	19
631	Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinsonâ€™s Disease. Molecules, 2020, 25, 453.	1.7	30
632	Cell-free microRNAs in Parkinsonâ€™s disease: potential biomarkers that provide new insights into disease pathogenesis. Ageing Research Reviews, 2020, 58, 101023.	5.0	18
633	Parkinson disease and the immune system â€" associations, mechanisms and therapeutics. Nature Reviews Neurology, 2020, 16, 303-318.	4.9	254
634	Mitochondrial <scp>DNA</scp> in inflammation and immunity. EMBO Reports, 2020, 21, e49799.	2.0	446
635	The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinsonâ€™s Disease. Cells, 2020, 9, 841.	1.8	51
636	Anti-Inflammatory and Anti-Migratory Activities of Isoquinoline-1-Carboxamide Derivatives in LPS-Treated BV2 Microglial Cells via Inhibition of MAPKs/NF-ÎºB Pathway. International Journal of Molecular Sciences, 2020, 21, 2319.	1.8	32
637	Combined 1-Deoxynojirimycin and Ibuprofen Treatment Decreases Microglial Activation, Phagocytosis and Dopaminergic Degeneration in MPTP-Treated Mice. Journal of NeuroImmune Pharmacology, 2021, 16, 390-402.	2.1	21
638	Peripheral inflammation exacerbates Î±â€synuclein toxicity and neuropathology in Parkinson's models. Neuropathology and Applied Neurobiology, 2021, 47, 43-60.	1.8	53
639	Ferroptosis and its potential role in the physiopathology of Parkinsonâ€™s Disease. Progress in Neurobiology, 2021, 196, 101890.	2.8	220
640	Inflammation in Experimental Models of Î±<scp>â€Synucleinopathies</scp>. Movement Disorders, 2021, 36, 37-49.	2.2	24
641	Cypermethrin Induces the Activation of Rat Primary Microglia and Expression of Inflammatory Proteins. Journal of Molecular Neuroscience, 2021, 71, 1275-1283.	1.1	3
642	Battery-free, wireless, and flexible electrochemical patch for in situ analysis of sweat cortisol via near field communication. Biosensors and Bioelectronics, 2021, 172, 112782.	5.3	82
643	Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases. Immunology, 2021, 162, 160-178.	2.0	12
644	Immunomodulation with IL-17 and TNF-Î± in spondyloarthritis: focus on the eye and the central nervous system. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110258.	1.2	5

#	Article	IF	Citations
645	Optimization of Lipophilic Metalloporphyrins Modifies Disease Outcomes in a Rat Model of Parkinsonism. Journal of Pharmacology and Experimental Therapeutics, 2021, 377, 1-10.	1.3	2
646	Repurposing GLP-1 Receptor Agonists for Parkinsonâ€™s Disease: Current Evidence and Future Opportunities. Pharmaceutical Medicine, 2021, 35, 11-19.	1.0	5
648	Broader Insights into Understanding Tumor Necrosis Factor and Neurodegenerative Disease Pathogenesis Infer New Therapeutic Approaches. Journal of Alzheimer's Disease, 2021, 79, 931-948.	1.2	15
649	Parkinsonâ€™s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?. Frontiers in Neuroscience, 2020, 14, 580311.	1.4	15
652	Alpha-Synuclein in the Regulation of Brain Endothelial and Perivascular Cells: Gaps and Future Perspectives. Frontiers in Immunology, 2021, 12, 611761.	2.2	22
653	Microglia-Secreted Factors Enhance Dopaminergic Differentiation of Tissue- and iPSC-Derived Human Neural Stem Cells. Stem Cell Reports, 2021, 16, 281-294.	2.3	23
654	Cytokine Profile in Plasma Extracellular Vesicles of Parkinsonâ€™s Disease and the Association with Cognitive Function. Cells, 2021, 10, 604.	1.8	21
655	Antioxidant Therapeutics in Parkinsonâ€™s Disease: Current Challenges and Opportunities. Antioxidants, 2021, 10, 453.	2.2	33
656	Mechanisms of Neurodegeneration in Various Forms of Parkinsonismâ€"Similarities and Differences. Cells, 2021, 10, 656.	1.8	25
657	Interferon-Î³ Involvement in the Neuroinflammation Associated with Parkinsonâ€™s Disease and L-DOPA-Induced Dyskinesia. Neurotoxicity Research, 2021, 39, 705-719.	1.3	9
658	N-Adamantyl Phthalimidine: A New Thalidomide-like Drug That Lacks Cereblon Binding and Mitigates Neuronal and Synaptic Loss, Neuroinflammation, and Behavioral Deficits in Traumatic Brain Injury and LPS Challenge. ACS Pharmacology and Translational Science, 2021, 4, 980-1000.	2.5	14
659	CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson'sÂdisease. Brain, 2021, 144, 2047-2059.	3.7	124
660	Inflammatory Responses to Monomeric and Aggregated Î±-Synuclein in Peripheral Blood of Parkinson Disease Patients. Frontiers in Neuroscience, 2021, 15, 639646.	1.4	23
661	Is LRRK2 the missing link between inflammatory bowel disease and Parkinsonâ€™s disease?. Npj Parkinson's Disease, 2021, 7, 26.	2.5	46
662	G-CSF reduces loss of dopaminergic neurons by inhibiting TNF-Î± and IL-1Î² in mouse model of Parkinsonâ€™s disease. International Journal of Neuroscience, 2023, 133, 278-289.	0.8	0
663	Neuro-Immune Cross-Talk in the Striatum: From Basal Ganglia Physiology to Circuit Dysfunction. Frontiers in Immunology, 2021, 12, 644294.	2.2	16
664	T Cells Limit Accumulation of Aggregate Pathology Following Intrastriatal Injection of Î±-Synuclein Fibrils. Journal of Parkinson's Disease, 2021, 11, 585-603.	1.5	14
666	Epigenetic Regulation of Neuroinflammation in Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 4956.	1.8	40

#	Article	IF	Citations
667	Oxidative stress and regulated cell death in Parkinsonâ€™s disease. Ageing Research Reviews, 2021, 67, 101263.	5.0	162
668	Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 41.	2.5	32
669	The efficacy of systemic administration of lipopolysaccharide in modelling pre-motor Parkinsonâ€™s disease in C57BL/6 mice. NeuroToxicology, 2021, 85, 254-264.	1.4	8
670	Molecular Communication Between Neuronal Networks and Intestinal Epithelial Cells in Gut Inflammation and Parkinson's Disease. Frontiers in Medicine, 2021, 8, 655123.	1.2	11
671	TNFÎ± increases tyrosine hydroxylase expression in human monocytes. Npj Parkinson's Disease, 2021, 7, 62.	2.5	10
672	Noscapine Prevents Rotenone-Induced Neurotoxicity: Involvement of Oxidative Stress, Neuroinflammation and Autophagy Pathways. Molecules, 2021, 26, 4627.	1.7	9
673	DRD4 (Dopamine D4 Receptor) Mitigate Abdominal Aortic Aneurysm via Decreasing P38 MAPK (mitogen-activated protein kinase)/NOX4 (NADPH Oxidase 4) Axisâ€"Associated Oxidative Stress. Hypertension, 2021, 78, 294-307.	1.3	10
674	Astrocytes in Neurodegenerative Diseases: A Perspective from Tauopathy and Î±-Synucleinopathy. Life, 2021, 11, 938.	1.1	13
675	Neurodegenerative disorders and the current state, pathophysiology and management of Parkinsonâ€™s disease. CNS and Neurological Disorders - Drug Targets, 2021, 20, .	0.8	0
676	Mitochondrial dysfunction in adult midbrain dopamine neurons triggers an early immune response. PLoS Genetics, 2021, 17, e1009822.	1.5	8
677	Role of Inflammation in Lewy Body Dementia. , 2021, , 190-212.		0
678	Multifaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeutic Perspectives. International Journal of Molecular Sciences, 2021, 22, 1413.	1.8	76
679	Inflammation in parkinsonâ€™s disease. Sub-Cellular Biochemistry, 2007, , 249-279.	1.0	26
680	Inflammatory Changes and Apoptosis in Parkinsonâ€™s Disease. Advances in Behavioral Biology, 2002, , 259-263.	0.2	2
681	Cytokines in CNS Inflammation and Disease. , 2008, , 59-106.		17
682	TNF: A Key Neuroinflammatory Mediator of Neurotoxicity and Neurodegeneration in Models of Parkinsonâ€™s Disease. Advances in Experimental Medicine and Biology, 2011, 691, 539-540.	0.8	59
683	Prospects for New Treatment Options in Neurodegenerative Diseases. , 2012, , 165-171.		1
684	Neuroinflammation and Parkinsonâ€™s Disease. , 2014, , 885-912.		1

#	Article	IF	Citations
685	Cytokines in Parkinsonâ€™s Disease. Advances in Behavioral Biology, 1998, , 407-412.	0.2	2
686	Prenatal Lipopolysaccharide Alters Postnatal Dopamine in the Laboratory Rat. Advances in Behavioral Biology, 2002, , 209-212.	0.2	3
688	Inflammatory Mediators in Alzheimerâ€™s Disease. , 1997, , 177-198.		11
689	Tumor Necrosis Factor. , 1998, , 163-183.		6
690	Targeting Purinergic Signaling and Cell Therapy in Cardiovascular and Neurodegenerative Diseases. Advances in Experimental Medicine and Biology, 2019, 1201, 275-353.	0.8	8
691	Biochemistry of postmortem brains in Parkinsonâ€™s disease: historical overview and future prospects. , 2007, , 113-120.		138
692	Parkinsonâ€™s Disease and Aging. , 2016, , 229-255.		1
693	Selegiline as immunostimulant â€" a novel mechanism of action?. Journal of Neural Transmission Supplementum, 1998, 52, 321-328.	0.5	29
694	Apoptosis in neurodegenerative disorders. Journal of Neural Transmission Supplementum, 1997, 50, 125-140.	0.5	52
695	Parkinsonâ€™s Disease; Neurodegeneration as Systemic Disease. , 2015, , 69-87.		1
696	Microglia in Parkinsonâ€™s Disease. Advances in Experimental Medicine and Biology, 2019, 1175, 335-353.	0.8	137
697	MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinsonâ€™s disease: neuroprotective strategies. Journal of Neurology, 2000, 247, II95-II102.	1.8	78
699	Tumor Necrosis Factor-Î±. Stroke, 1997, 28, 1233-1244.	1.0	708
700	Increased Mitochondrial Calcium Sensitivity and Abnormal Expression of Innate Immunity Genes Precede Dopaminergic Defects in Pink1-Deficient Mice. PLoS ONE, 2011, 6, e16038.	1.1	154
701	Fractalkine Signaling Regulates the Inflammatory Response in an Î±-Synuclein Model of Parkinson Disease. PLoS ONE, 2015, 10, e0140566.	1.1	54
702	ASIC1a Deficient Mice Show Unaltered Neurodegeneration in the Subacute MPTP Model of Parkinson Disease. PLoS ONE, 2016, 11, e0165235.	1.1	14
703	Abrogation of the Circadian Nuclear Receptor REV-ERBÎ± Exacerbates 6-Hydroxydopamine-Induced Dopaminergic Neurodegeneration. Molecules and Cells, 2018, 41, 742-752.	1.0	12
704	Connecting cytokines and brain: a review of current issues. Histology and Histopathology, 2002, 17, 273-88.	0.5	84

#	Article	IF	Citations
705	Resveratrol Normalizes Hyperammonemia Induced Pro-Inflammatory and Pro-Apoptotic Conditions in Rat Brain. International Journal of Complementary & Alternative Medicine, 2016, 4, .	0.1	3
706	Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinsonâ€™s Disease. Current Medicinal Chemistry, 2019, 26, 3719-3753.	1.2	45
707	The Role of LRRK2 in Neurodegeneration of Parkinson Disease. Current Neuropharmacology, 2018, 16, 1348-1357.	1.4	95
708	Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases. CNS and Neurological Disorders - Drug Targets, 2011, 10, 391-403.	0.8	192
709	Strategic Selection of Neuroinflammatory Models in Parkinson's Disease: Evidence from Experimental Studies. CNS and Neurological Disorders - Drug Targets, 2013, 12, 680-697.	0.8	29
710	Role of Environmental and Inflammatory Toxicity in Neuronal Cell Death. The Open Toxicology Journal, 2008, 2, 26-41.	1.0	1
711	Cellular Senescence in Neurodegenerative Diseases. Frontiers in Cellular Neuroscience, 2020, 14, 16.	1.8	164
712	TNF-Mediated Homeostatic Synaptic Plasticity: From in vitro to in vivo Models. Frontiers in Cellular Neuroscience, 2020, 14, 565841.	1.8	53
713	Chemically Induced Models of Parkinsonâ€™s Disease: History and Perspectives for the Involvement of Ferroptosis. Frontiers in Cellular Neuroscience, 2020, 14, 581191.	1.8	27
714	LRRK2 at the Interface Between Peripheral and Central Immune Function in Parkinsonâ€™s. Frontiers in Neuroscience, 2020, 14, 443.	1.4	47
715	The N-formyl peptide receptors: contemporary roles in neuronal function and dysfunction. Neural Regeneration Research, 2020, 15, 1191.	1.6	12
716	Elevated levels of Interleukin (IL)-1Î², IL-6, tumor necrosis factor-Î±, epidermal growth factor, and Î²2-microglobulin levels in gingival crevicular fluid during human Orthodontic tooth movement (OTM). Journal of Family Medicine and Primary Care, 2019, 8, 1602.	0.3	20
717	Parkinson's disease: Microglial/macrophage-induced immunoexcitotoxicity as a central mechanism of neurodegeneration. , 2017, 8, 65.		50
718	The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Reports, 2010, 43, 225-232.	1.1	134
719	Reactive Oxygen Species in Neurodegenerative Diseases: Implications in Pathogenesis and Treatment Strategies. Biochemistry, 0, , .	0.8	5
720	Mitochondrial Dysfunction, Protein Misfolding and Neuroinflammation in Parkinsonâ€™s Disease: Roads to Biomarker Discovery. Biomolecules, 2021, 11, 1508.	1.8	59
721	Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption. Nature Communications, 2021, 12, 5907.	5.8	97
722	Ferroptosis Mediated by Lipid Reactive Oxygen Species: A Possible Causal Link of Neuroinflammation to Neurological Disorders. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-13.	1.9	53

#	Article	IF	Citations
723	Contribution of Intracellular Non-Haem Iron, NF-kB Activation and Inflammatory Responses to Neurodegeneration in Parkinsonâ€™s Disease: Prospects for Neuroprotection. , 2000, , 277-288.		0
724	Cytokines and Neurotrophins in Parkinsonâ€™s Disease: Involvement in Apoptosis. Advances in Behavioral Biology, 2002, , 265-270.	0.2	0
725	Cytokines and Neurodegeneration. , 2005, , 163-191.		0
726	The In Vitro and In Vivo Molecular Mechanisms of Neuroprotection by the Major Green Tea Polyphenol, (â€“)-Epigallocatechin-3-gallate, with Special Reference to Parkinsonâ€™s Disease. Oxidative Stress and Disease, 2005, , 155-174.	0.3	0
728	CFS Biomarkers in Parkinsonâ€™s Disease. , 0, , .		0
729	Inflammatory Responses and Regulation in Parkinsonâ€™s Disease. , 0, , .		0
730	Role of Microglia in Inflammatory Process in Parkinsonâ€™s Disease. , 0, , .		0
731	Inflammation in Parkinsonâ€™s Disease: Causes and Consequences. , 0, , .		0
732	Association of Serum Interferon Gamma Level with Parkinson's : Disease in Egyptian Patients. Egyptian Journal of Medical Microbiology, 2014, 23, 1-5.	0.1	1
733	Contribution of Receptors, Transcription Factors, and Genes in the Induction of Neuroinflammation. , 2014, , 111-142.		0
734	Proinflammatory Chemical Signaling: Cytokines. , 2014, , 145-173.		15
737	Supporting evidence for using perispinal etanercept to inhibit TNFÎ± when treating neuropathologies including dementia, chronic stroke, neuropathic pain or traumatic brain injury: Clinical outcomes and role of TNF in neuropathologies other than Alzheimerâ€™s Dementia (Part III). Healthy Aging Research, 0, , .	0.3	1
738	Role of Adenosine A2A Receptors in the Control of Neuroinflammationâ€"Relevance for Parkinsonâ€™s Disease. Current Topics in Neurotoxicity, 2015, , 81-99.	0.4	0
740	Changes in the Immune System in Parkinsonâ€™s Disease. , 2018, , 1-21.		0
741	Changes in the Immune System in Parkinsonâ€™s Disease. , 2019, , 2353-2373.		0
742	Monoamine Oxidase Inhibitor (MAO-I)-Mediated Neuroprotection for Treating Parkinsonâ€™s Disease. , 2020, , 1-21.		0
744	Neurobiological Principles: Psycho-Neuro-Immuno-Endocrinology. , 2020, , 1-40.		1
747	Dopamine inhibits the expression of proinflammatory cytokines of microglial cells through the formation of dopamine quinone in the mouse striatum. Journal of Pharmacological Sciences, 2022, 148, 41-50.	1.1	3

#	Article	IF	Citations
748	Neurons and Plasticity: What Do Glial Cells Have to Do with This?. Brain Informatics and Health, 2020, , 13-46.	0.1	0
749	Neuroprotective Immunity for Neurodegenerative and Neuroinfectious Diseases. , 2020, , 335-370.		0
753	Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapies. Neuropharmacology, 2022, 202, 108870.	2.0	14
754	NF-ÎºB in Aging and Disease. , 2011, 2, 449-65.		150
757	Neuroprotective effect of fasudil on inflammation through PI3K/Akt and Wnt/Î²-catenin dependent pathways in a mice model of Parkinson's disease. International Journal of Clinical and Experimental Pathology, 2015, 8, 2354-64.	0.5	25
759	Multi-omic insights into Parkinson's Disease: From genetic associations to functional mechanisms. Neurobiology of Disease, 2022, 163, 105580.	2.1	20
760	Efficacy of Human Umbilical Cord Blood-Mononuclear Cell Transplantation for MSA Treatment and Its Effects on Changes in T-Cell Subsets in Peripheral Blood and Inflammatory Factors. Disease Markers, 2021, 2021, 1-7.	0.6	1
761	Immune response during idiopathic Parkinson's disease: From humans to animal models. International Review of Movement Disorders, 2021, 2, 261-301.	0.1	1
762	Dopaminergic neuronal death in the substantia nigra associates with change in serum levels of TNF-Î± and IL-1Î²; evidence from early experimental model of Parkinsonâ€™s disease. Neurological Research, 2022, 44, 544-553.	0.6	4
763	Additive cell protective and oxidative stress reducing effects of combined treatment with cromolyn sodium and masitinib on MPTP-induced toxicity in SH-SY5Y neuroblastoma cells. Chemico-Biological Interactions, 2022, 354, 109808.	1.7	2
764	A Perspective on Nrf2 Signaling Pathway for Neuroinflammation: A Potential Therapeutic Target in Alzheimer's and Parkinson's Diseases. Frontiers in Cellular Neuroscience, 2021, 15, 787258.	1.8	62
765	Phytochemicals as inhibitors of tumor necrosis factor alpha and neuroinflammatory responses in neurodegenerative diseases. Neural Regeneration Research, 2022, 17, 1675.	1.6	23
766	Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients. Journal of Neuroinflammation, 2022, 19, 19.	3.1	82
767	Neurodegeneration by Î±-synuclein-specific T cells in AAV-A53T-Î±-synuclein Parkinsonâ€™s disease mice. Brain, Behavior, and Immunity, 2022, 101, 194-210.	2.0	34
768	Role of exosomes in the pathogenesis of inflammation in Parkinsonâ€™s disease. Neural Regeneration Research, 2022, 17, 1898.	1.6	32
769	The Neuroinflammatory Acute Phase Response in Parkinsonianâ€Related Disorders. Movement Disorders, 2022, 37, 993-1003.	2.2	8
770	Mitochondria-targeted drug delivery systems for the effective treatment of neurodegenerative disorders. , 2022, , 129-150.		0
771	Immunotherapeutic interventions in Parkinson's disease: Focus on Î±-Synuclein. Advances in Protein Chemistry and Structural Biology, 2022, 129, 381-433.	1.0	3

#	Article	IF	Citations
772	Leukotriene Signaling as a Target in Î±-Synucleinopathies. Biomolecules, 2022, 12, 346.	1.8	5
773	CSF and Serum Levels of Inflammatory Markers in PD: Sparse Correlation, Sex Differences and Association With Neurodegenerative Biomarkers. Frontiers in Neurology, 2022, 13, 834580.	1.1	17
774	Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys. Cells, 2022, 11, 691.	1.8	8
775	Tracking Innate Immune Activation in a Mouse Model of Parkinsonâ€™s Disease Using TREM1 and TSPO PET Tracers. Journal of Nuclear Medicine, 2022, 63, 1570-1578.	2.8	8
776	Kurarinone alleviated Parkinson's disease via stabilization of epoxyeicosatrienoic acids in animal model. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	37
777	Central Inflammatory Cytokines in Tuberculous Meningitis: A Systematic Review and Meta-analysis. Journal of Interferon and Cytokine Research, 2022, 42, 95-107.	0.5	12
778	Inflammation and immune dysfunction in Parkinson disease. Nature Reviews Immunology, 2022, 22, 657-673.	10.6	360
779	Treatment; Moussa B.H. Youdim. Journal of Neural Transmission, 2022, , 1.	1.4	0
780	Reducing neuroinflammation via therapeutic compounds and lifestyle to prevent or delay progression of Parkinsonâ€™s disease. Ageing Research Reviews, 2022, 78, 101618.	5.0	28
781	Biomarker of Neuroinflammation in Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 4148.	1.8	50
782	Immune responses in the Parkinson's disease brain. Neurobiology of Disease, 2022, 168, 105700.	2.1	30
784	Glial-Neuronal Interactions during Oxidative Stress: Implications for Parkinson's Disease. , 0, , 407-419.		0
792	Diagnosis of Parkinson's disease by investigating the inhibitory effect of serum components on P450 inhibition assay. Scientific Reports, 2022, 12, 6622.	1.6	3
793	Microorganisms associated with increased risk of Parkinsonâ€™s disease. NeurologÃa (English Edition), 2022, , .	0.2	1
794	Immune-related biomarkers for Parkinson's disease. Neurobiology of Disease, 2022, 170, 105771.	2.1	13
795	Neuroinflammation in Parkinsonâ€™s Disease â€“ Putative Pathomechanisms and Targets for Disease-Modification. Frontiers in Immunology, 2022, 13, .	2.2	42
796	Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, S183-S200.	1.5	16
797	Leveraging the preformed fibril model to distinguish between alpha-synuclein inclusion- and nigrostriatal degeneration-associated immunogenicity. Neurobiology of Disease, 2022, 171, 105804.	2.1	12

#	Article	IF	Citations
798	DAT and TH expression marks human Parkinsonâ€™s disease in peripheral immune cells. Npj Parkinson's Disease, 2022, 8, .	2.5	16
799	Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated Î±-synuclein mouse model of Parkinson's disease. Neurobiology of Disease, 2022, 171, 105798.	2.1	8
800	NF-ÎºB Regulation by Gut Microbiota Decides Homeostasis or Disease Outcome During Ageing. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	8
801	The Role of ASIC1a in Inflammatory Immune Diseases: A Potential Therapeutic Target. Frontiers in Pharmacology, 0, 13, .	1.6	1
802	Efficacy of Phytochemicals and Natural Products in the Management/Treatment of Neurodegenerative Diseases. Advances in Medical Diagnosis, Treatment, and Care, 2022, , 178-210.	0.1	0
803	G2019S LRRK2 Mutation Enhances MPP+-Induced Inflammation of Human Induced Pluripotent Stem Cells-Differentiated Dopaminergic Neurons. Frontiers in Neuroscience, 0, 16, .	1.4	1
804	Neuroinflammation in early, late and recovery stages in a progressive parkinsonism model in rats. Frontiers in Neuroscience, 0, 16, .	1.4	3
805	Genome integrity and inflammation in the nervous system. DNA Repair, 2022, 119, 103406.	1.3	4
806	Neuroinflammation and Parkinsonâ€™s Diseaseâ€"From Neurodegeneration to Therapeutic Opportunities. Cells, 2022, 11, 2908.	1.8	28
808	Activity of a Novel Anti-Inflammatory Agent F-3,6â€²-dithiopomalidomide as a Treatment for Traumatic Brain Injury. Biomedicines, 2022, 10, 2449.	1.4	4
809	Trimethylamine N-oxide: role in cell senescence and age-related diseases. European Journal of Nutrition, 0, , .	1.8	3
811	Unraveling Parkinsonâ€™s Disease Neurodegeneration: Does Aging Hold the Clues?. Journal of Parkinson's Disease, 2022, 12, 2321-2338.	1.5	9
812	Effect of citronellol on oxidative stress, neuroinflammation and autophagy pathways in an in vivo model of Parkinson's disease. Heliyon, 2022, 8, e11434.	1.4	16
813	Monoamine Oxidase Inhibitor (MAO-I)-Mediated Neuroprotection for Treating Parkinsonâ€™s Disease. , 2022, , 3127-3147.		0
814	Neurobiological Principles: Psycho-Neuro-Immuno-Endocrinology. , 2022, , 25-63.		0
815	Microglia and astrocyte activation is regionâ€dependent in the Î±â€synuclein mouse model of Parkinson's disease. Glia, 2023, 71, 571-587.	2.5	14
816	A Combined Panel of Salivary Biomarkers in de novo Parkinson's Disease. Annals of Neurology, 2023, 93, 446-459.	2.8	14
817	The Immunomodulatory Potential Role of Mesenchymal Stem Cells in Diseases of the Central Nervous System. Neurodegenerative Diseases, 2022, 22, 68-82.	0.8	6

#	Article	IF	Citations
818	The complex role of inflammation and gliotransmitters in Parkinson's disease. Neurobiology of Disease, 2023, 176, 105940.	2.1	8
819	Altered expression of glycobiology-related genes in Parkinsonâ€™s disease brain. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	5
820	Pathogenesis of Î±-Synuclein in Parkinsonâ€™s Disease: From a Neuron-Glia Crosstalk Perspective. International Journal of Molecular Sciences, 2022, 23, 14753.	1.8	14
821	Mechanisms of Autoimmune Cell in DA Neuron Apoptosis of Parkinsonâ€™s Disease: Recent Advancement. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-20.	1.9	5
822	Association between Heavy Metal Exposure and Parkinsonâ€™s Disease: A Review of the Mechanisms Related to Oxidative Stress. Antioxidants, 2022, 11, 2467.	2.2	20
823	Dopamine, Immunity, and Disease. Pharmacological Reviews, 2023, 75, 62-158.	7.1	43
824	Microglial autophagy in Alzheimerâ€™s disease and Parkinsonâ€™s disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	6
825	Silibinin chronic treatment in a rat model of Parkinson disease: A comprehensive in-vivo evaluation and in silico molecular modeling. European Journal of Pharmacology, 2023, , 175517.	1.7	3
826	Linagliptin counteracts rotenoneâ€™s toxicity in non-diabetic rat model of Parkinsonâ€™s disease: Insights into the neuroprotective roles of DJ-1, SIRT-1/Nrf-2 and implications of HIF1-Î±. European Journal of Pharmacology, 2023, 941, 175498.	1.7	1
827	Kinases control of regulated cell death revealing druggable targets for Parkinsonâ€™s disease. Ageing Research Reviews, 2023, 85, 101841.	5.0	12
828	Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-Î±-synuclein Parkinsonâ€™s disease mice. Journal of Neuroinflammation, 2022, 19, .	3.1	8
829	Three-Dimensional Analysis of Sex- and Gonadal Status- Dependent Microglial Activation in a Mouse Model of Parkinsonâ€™s Disease. Pharmaceuticals, 2023, 16, 152.	1.7	3
830	Deep brain stimulation improves central nervous system inflammation in Parkinson's disease: Evidence and perspectives. CNS Neuroscience and Therapeutics, 2023, 29, 2177-2185.	1.9	3
831	Investigating Therapeutic Effects of Indole Derivatives Targeting Inflammation and Oxidative Stress in Neurotoxin-Induced Cell and Mouse Models of Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2023, 24, 2642.	1.8	8
833	Systemic lupus erythematosus is associated with increased risk of Parkinsonâ€™s disease. Therapeutic Advances in Musculoskeletal Disease, 2023, 15, 1759720X2311526.	1.2	0
834	Serum inflammatory cytokines levels and the correlation analyses in Parkinsonâ€™s disease. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	2
835	Disease mechanisms as subtypes: Immune dysfunction in Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 67-93.	1.0	0
836	Disease mechanisms as subtypes: Inflammation in Parkinson disease and related disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 95-106.	1.0	4

#	Article	IF	Citations
837	Signaling pathways in Parkinsonâ€™s disease: molecular mechanisms and therapeutic interventions. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	37
838	Voltage-Gated Proton Channel Hv1 Regulates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinsonâ€™s Disease Models. Antioxidants, 2023, 12, 582.	2.2	3
839	Brain and Systemic Inflammation in De Novo Parkinson's Disease. Movement Disorders, 2023, 38, 743-754.	2.2	12
840	Quantitative and causal analysis for inflammatory genes and the risk of Parkinsonâ€™s disease. Frontiers in Immunology, 0, 14, .	2.2	4
841	Cytokine profiles of plasma extracellular vesicles as progression biomarkers in Parkinsonâ€™s disease. Aging, 0, , .	1.4	2
842	Inflammatory CSF profiles and longitudinal development of cognitive decline in sporadic and GBA-associated PD. Npj Parkinson's Disease, 2023, 9, .	2.5	4
843	Anti-Inflammatory Effect of Traditional Chinese Medicine on the Concept of Mind-Body Interface. Advances in Experimental Medicine and Biology, 2023, , 435-458.	0.8	2
844	Roles of neuropathology-associated reactive astrocytes: a systematic review. Acta Neuropathologica Communications, 2023, 11, .	2.4	40
845	Association between Inflammatory Bowel Disease and Subsequent Development of Restless Legs Syndrome and Parkinsonâ€™s Disease: A Retrospective Cohort Study of 35,988 Primary Care Patients in Germany. Life, 2023, 13, 897.	1.1	0
846	Microglia and Astrocytes Dysfunction and Key Neuroinflammation-Based Biomarkers in Parkinsonâ€™s Disease. Brain Sciences, 2023, 13, 634.	1.1	7
847	Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinsonâ€™s disease. Journal of Neural Transmission, 2023, 130, 627-646.	1.4	8
852	Immunity and cognition. , 2023, , 129-149.		0
857	Diagnostic Biomarkers of Parkinson's Disease. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 64-80.	0.1	0
879	Free water imaging in Parkinsonâ€™s disease and atypical parkinsonian disorders. Journal of Neurology, 2024, 271, 2521-2528.	1.8	0